Genomic insights into extrapulmonary tuberculosis reveal enrichment of lineage 2 with high drug resistance in specific clinical phenotypes

Genomic insights into extrapulmonary tuberculosis reveal enrichment of lineage 2 with high drug resistance in specific clinical phenotypes | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Genomic insights into extrapulmonary tuberculosis reveal enrichment of lineage 2 with high drug resistance in specific clinical phenotypes Kusum Sharma, Aravind Bandari, Gowrang Kasaba Manjunath, Mona Rastogi, and 20 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7813203/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 15 You are reading this latest preprint version Abstract Background Certain M. tuberculosis lineages may preferentially infect extrapulmonary sites, potentially influencing clinical outcomes. Poor drug penetration at these sites may cause treatment failure, even in the absence of resistance. Timely access to resistance profiles and lineage information may support more effective, personalized treatment for extrapulmonary tuberculosis (EPTB). We sequenced 117 M. tuberculosis culture isolates from seven EPTB sites at PGIMER, Chandigarh, India. This included cerebrospinal fluid (CSF, n = 40), pus (n = 35), fine-needle aspiration cytology (FNAC, n = 22), tissue (n = 8), ileocaecal biopsy (n = 6), synovial fluid (n = 5), and vitreous fluid (n = 1). Phenotypic drug susceptibility testing (pDST) against 12 drugs was performed using the MYCOTBI sensititre assay. Whole genome sequencing (WGS) on Illumina XTen platform and analyzed using in-house pipelines. Results Drug resistance was identified in 23.9% (28/117) of isolates by pDST and 29.9% (35/117) by WGS, with 93.0% concordance. WGS detected additional resistant cases missed by MYCOTBI (p = 0.039). Resistance was significantly associated with sample type (p = 0.0446), highest in CSF (16/40, 40.0%). Lineage 2 had the highest resistance (13/24, 54.1%), primarily from CSF (9/13, 69.2%). Mixed infections were observed in 6.8% (8/117) of isolates, mostly involving lineages 2 and 3. Heteroresistance was more common in mixed infections (p = 0.0139). Conclusions WGS reliably detected resistance to anti-TB drugs, along with lineage and mixed infections. This approach can be applied in culture-free targeted sequencing for rapid detection of resistance and lineage, enabling personalized treatment regimens and improved outcomes in EPTB. EPTB lineage drug resistance whole genome sequencing MYCOTBI Figures Figure 1 Figure 2 Figure 3 Figure 4 BACKGROUND EPTB accounts for 15–20% of the global TB burden [ 1 ] and is associated with high mortality, poor treatment outcomes, and increased relapse rates [ 2 – 5 ]. Recent studies have reported rising drug resistance among EPTB patients, complicating diagnosis and disease management [ 6 , 7 ]. Drug resistance in EPTB ranges from 10–20%, with up to 40% resistance reported against first-line anti-TB drugs [ 8 ]. Despite these challenges, current guidelines largely recommend uniform treatment regimens for pulmonary TB and EPTB [ 9 ]. However, anti-TB drugs show lower penetration at certain extrapulmonary sites, such as CSF, leading to subtherapeutic levels and possible treatment failure [ 10 ]. In such cases, poor drug exposure rather than microbial resistance may contribute to adverse outcomes. Dose adjustments based on the clinical phenotype and resistance profile may improve outcomes [ 11 ]. Compounding these challenges, clinicians often lack complete resistance profiles to distinguish between pharmacokinetic failure and true resistance due to challenges in detecting drug resistance in EPTB samples. In addition, M. tuberculosis lineage influences disease severity, transmission dynamics, and resistance development [ 12 ]. Some lineages exhibit higher virulence, increased drug resistance, and stronger associations with specific anatomical sites in pulmonary TB [ 13 ], yet their role in EPTB remains underexplored. Diagnosing drug resistance in EPTB is further complicated by its paucibacillary nature and low culture positivity [ 6 ]. Resistance is frequently suspected only after clinical non-response [ 14 ]. The WHO recommends molecular assays like GeneXpert MTB/RIF and GeneXpert MTB/RIF Ultra for rapid detection of M. tuberculosis and rifampicin resistance, though these tools detect limited mutations [ 2 ]. Studies have identified resistance to both first- and second-line drugs in EPTB [ 15 , 16 ]. Targeted sequencing platforms, informed by the WHO mutation catalogue, enable rapid, culture-free detection of resistance mutations and lineage assignment [ 17 , 18 ]. However, these panels are primarily developed using data from pulmonary TB [ 19 ]. Furthermore, phenotypic-genotype data for drugs like ofloxacin, cycloserine, para-aminosalicylic acid (PAS), and rifabutin are not included in the current WHO catalogue, despite evidence of resistance-linked mutations [ 20 – 22 ]. In this study, we performed WGS of M. tuberculosis isolates from seven extrapulmonary sites and compared genotypic resistance with MYCOTBI phenotypic DST across twelve anti-TB drugs. We also examined heteroresistance, mixed infections, and associations between lineage, drug resistance, and clinical phenotype. METHODS Patient enrollment and ethical statement We used M. tuberculosis positive culture isolates from extrapulmonary sites collected between 2014–2020 at the Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The study was approved by the PGIMER Institutional Ethics Committee (Reference No. NK/1691/Res/3286). All participants were aged 18 years or older and provided written consent before the initiation of the study. Sample processing and DNA extraction A total of 117 M. tuberculosis positive cultures were collected from seven extrapulmonary sites. These included CSF (n = 40), pus (n = 35), fine-needle aspiration cytology (FNAC) (n = 22), tissue (n = 8), ileocaecal biopsy (ICBx) (n = 6), synovial fluid (SF) (n = 5) and vitreous fluid (VF) (n = 1). All the isolates were processed as per the standard protocol described previously [ 23 ]. The samples were inoculated to Mycobacteria Growth Indicator Tube (MGIT) and solid culture Lowenstein-Jensen (LJ) slants (Difco Lowenstein Medium Base No. 244420) and incubated at 37˚C for eight weeks. The cultures were subsequently tested using commercially available SD BIOLINE TB Ag MPT64 rapid kit to rule out non-tuberculous mycobacteria. DNA was extracted using QIAamp DNA Mini Kit, according to the manufacturer’s instructions, eluted in 50µl nuclease-free water and stored at -20°C until use. Sensititre MYCOTB assay We performed minimum inhibitory concentration (MIC) based phenotypic DST using MYCOTBI sensititre plates (Sensititre MYCOTB assay, Thermo Fisher Scientific, USA) on all culture-positive samples (n = 117) according to the manufacturer's instructions. The MYCOTBI plates are pre-coated with twelve standardized drug concentrations, including isoniazid, rifampicin, ethambutol, streptomycin, moxifloxacin, ofloxacin, cycloserine, PAS, rifabutin, amikacin, kanamycin, and ethionamide [ 24 ]. For MYCOTBI testing, mycobacterial strains isolated from extrapulmonary regions were subcultured onto LJ slants (Difco Lowenstein Medium Base No. 244420). Colonies with bacterial growth were added to 200 µl of saline-Tween 80 solution (Trek Diagnostic Systems) containing 0.5 mm silica beads and vortexed for 30 seconds. The colony suspension was allowed to settle for 10 minutes, and the turbidity of the sample was adjusted to match the 0.5 McFarland standard. A total of 100 µl of the adjusted saline suspension was transferred to 11 ml of Middlebrook 7H9 broth containing oleic acid-albumin-dextrose-catalase (Trek Diagnostic Systems) and mixed thoroughly. Then, 100 µl of the suspension was inoculated into each well of the MYCOTBI plate. The plates were sealed and incubated at 37°C in a 5% CO₂ atmosphere. Plates were monitored on days 7, 14, 21, and 28 post-inoculation using a manual plate reader with data management software (Vizion System, TREK Diagnostics). If the MIC value of a drug was higher than its critical concentration, the strain was classified as resistant; if it was equal to or below the critical concentration, the strain was classified as sensitive. Each MYCOTBI plate was independently read, interpreted, and recorded by two readers to ensure agreement. For phenotype-to-genotype comparisons of drug resistance, the readings from day 28 were considered final. Library preparation Genomic DNA was quantified using the Qubit fluorometric method. DNA samples were prepared for library construction using the Twist EF Library Prep Kit for Illumina (Cat#100572). Initially, DNA was fragmented to the desired size, followed by end-repair and 3’ mono-adenylation in a single enzymatic reaction. Adapters were then ligated using a T4 DNA ligase-based reaction. Post-ligation, the libraries were PCR-amplified with unique barcoded primers (Twist Unique Dual Index Primer Set A, Cat#101308) for sample multiplexing. Fragment distribution was assessed using the Agilent 5300 Fragment Analyzer System. The clustered libraries were sequenced on the Illumina HiSeq XTen platform to generate 150 bp paired-end reads. Variant mapping, annotation and phylogenetic analysis We used Snippy [ 25 ] for whole-genome alignment to the M. tuberculosis reference genome H37Rv (Acc: NC000962) and variant calling. Snippy is a freely available Perl-based tool capable of identifying both single nucleotide polymorphisms (SNPs) and indels. It leverages BWA-MEM [ 26 ] and FreeBayes [ 27 ]. We ran Snippy with default parameters, which have previously been shown to produce high-quality variant calls. Variants were annotated using SnpEff [ 28 ] with the H37Rv reference genome. Snippy-core was employed to generate core-alignment files. Gubbins v2.4.1 [ 29 ] was used to produce an alignment file with recombinant sites masked. A maximum-likelihood phylogenetic tree based on the core SNPs was constructed using IQ-TREE2 [ 30 ], with 1000 ultrafast bootstrap iterations and the GTR model. The generated phylogenetic tree was visualized and annotated using iTOL [ 31 ]. Drug Resistance and lineage identification: We used TBProfiler v6.5.0 to detect drug resistance and identify lineages [ 32 ]. TBProfiler aligns reads to the H37Rv reference genome using Bowtie2, BWA, or Minimap2, and then calls variants with BCFtools. After variant calling, the collate function extracts drug-resistance mutations and lineage information using a database of drug resistance mutations and lineage markers hosted on the TBDB repository [ 32 ]. Additionally, the identified mutations associated with drug resistance were compared against the WHO catalogue [ 33 ] to distinguish between mutations linked to drug resistance and those not associated with it. Heteroresistance detection We used an inhouse customized Python scripts [ 34 ] to detect heteroresistance in M. tuberculosis . Initially, we curated a database of mutations associated with antibiotic resistance [ 35 ]. Using the samtools mpileup command, we generated pileup files for specific genomic regions of interest from a sorted BAM file aligned to the reference genome of M. tuberculosis H37Rv . We then parsed these pileup files to calculate nucleotide frequencies at the mutation sites. Further, we processed each mutation entry by extracting the reference and mutant nucleotide frequencies, as well as the total read counts, to determine the presence and extent of heteroresistance. We used a minimum 10 reads cutoff to consider a mutation as true positive for heteroresistance detection. The calculated frequencies and read counts were subsequently compiled into an Excel report, sorted by mutant frequency to highlight significant mutations. Statistical analysis A Chi-square test was conducted to assess the presence of a significant association between sample type and drug resistance. Only sample types with a sample size of 10 or greater were included in the analysis. We also performed Chi-square test to determine if there was any significant correlation between sample type, lineage, and drug resistance. We performed McNemar’s test to compare the diagnostic performance of MYCOTBI phenotypic drug susceptibility testing with whole genome sequencing, considering WGS as the reference standard. All data analysis were performed in R. RESULTS Study participants and sample characteristics Of the 117 individuals with active EPTB whose positive culture isolates were used for the study, 58% (68/117) were male (median age = 37 years; IQR = 30–48). The median age of female participants was 33 years (IQR = 24.5–55.5). Samples were classified based on the site of infection, including CSF (40/117, 34.2%), pus (35/117, 29.9%), FNAC (22/117, 18.8%), tissue (8/117, 6.8%), ICBx (6/117, 5.1%), SF (5/117, 4.3%), and VF (1/117, 0.9%). The clinical and microbiological characteristics of the study cohort are summarized in Table 1 . MYCOTBI phenotypic drug susceptibility Of the seven different sample types, resistance to at least one drug tested in the MYCOTBI phenotypic drug susceptibility assay was observed in 28/117 (23.9%) M. tuberculosis isolates. These included samples from four sites, CSF (16/28, 57.1%), pus (8/28, 28.5%), synovial fluid (SF, 1/28, 3.5%), and FNAC (3/28, 10.7%). Based on MYCOTBI phenotypic DST, samples were identified as isoniazid-resistant TB (HR-TB, 17/117, 14.5%), rifampicin-resistant TB (RR-TB, 2/117, 1.7%), multidrug-resistant TB (MDR-TB, 1/117, 0.9%), and pre-extensively drug-resistant TB (Pre-XDR-TB, 8/117, 6.8%). We observed high levels of drug resistance to first-line anti-TB drugs. Isoniazid mono-resistance was the most prevalent (17/28, 60.7%), followed by resistance to ethambutol (13/117, 11.1%), rifampicin (11/117, 9.4%), and streptomycin (11/117, 9.4%). No resistance was detected to ofloxacin, cycloserine, PAS, or rifabutin in phenotypic drug susceptibility testing. ( Supplementary table 1 ). Whole genome sequencing and genotypic drug resistance All samples (n = 117) met the minimum quality criteria (Phred score ≥ 20, coverage depth ≥ 50x). The median H37Rv genome coverage across all samples was 99.1% (IQR = 99.3–99.8). The overall median coverage depth was 201x (IQR = 122.0–339.5). A summary of sequencing statistics is provided in Table 2 A. We observed higher median coverage depth in CSF (median 257.2x) and pus samples (median 320x) compared to other sample types (Fig. 1 ). We compared the variant calling data from WGS with the most recent version of the WHO mutation catalogue to identify drug resistance-associated mutations [ 33 ]. Mutation profiles for four drugs included in the MYCOTBI sensititre panel namely ofloxacin, cycloserine, PAS, and rifabutin are not present in the WHO mutation catalogue. However, substantial literature evidence supports the existence of drug resistance-associated mutations for these drugs [ 20 – 22 ]. These mutations are incorporated into the widely used TBProfiler platform [ 32 ]. We used the mutation profiles derived from TBProfiler for these drugs to assess genotype-to-phenotype concordance. Based on WGS analysis, 36/117 (30.7%) samples exhibited mutations associated with at least one drug included in the MYCOTBI test panel (Fig. 2 A, Supplementary Table 2 ). Seventeen unique mutations were identified in eight genes ( embA, embB, fabG1, katG, gyrA, pncA, rpoB, rrs ). The katG p.Ser315Thr mutation, which confers high-level resistance to isoniazid, was detected in 21/117 (17.9%) samples. Rifampicin resistance associated mutations were detected in 18/117 (15.3%) samples. These mutations are included in the GeneXpert MTB/RIF Ultra point-of-care test and are known to confer high-level rifampicin resistance [ 36 ]. The rpoB p.Ser450Leu mutation was the most prevalent, detected in 11/18 samples (61.1%), followed by rpoB p.His445Asn in 4/18 samples (22.2%), and rpoB p.Leu452Pro in 2/18 samples (11.1%). These mutations occur within the rifampicin resistance-determining region (RRDR) of the rpoB gene and are associated with high-level rifampicin resistance. Of the four drugs for which mutation profiles are not yet fully incorporated in the current WHO mutation catalogue, we detected mutations associated with ofloxacin resistance in 12 samples and rifabutin resistance in 18 out of 117 samples. According to WHO’s 2021 catalogue of mutations in M. tuberculosis , the p.Asp435Val mutation is classified as associated with rifampicin resistance but does not always confer resistance to rifabutin. The distribution of mutations across various samples is shown in Table 2 B. Phenotype-genotype agreement For the phenotype-to-genotype sensitivity analysis, we considered only those mutations listed in the WHO mutation catalogue as strongly associated with drug resistance. Based on this, WGS was selected as the reference standard to evaluate the sensitivity of the MYCOTBI drug DST for detecting resistance. A statistically significant difference in sensitivity between MYCOTBI DST and WGS was observed (McNemar’s p = 0.039). The MYCOTBI DST correctly identified 77.1% of resistant cases and 98.8% of sensitive cases as determined by WGS. These findings suggest that while MYCOTBI DST demonstrates high specificity (i.e., few false positives), it is less sensitive, missing approximately 23% of drug-resistant cases identified by WGS. Streptomycin exhibited the highest discordance between DST and WGS, with a difference observed in 22 cases. Additionally, two samples detected as rifampicin-sensitive by DST harbored rpoB p.His445Asn and rpoB p.Leu452Pro mutations, both known to confer high-level rifampicin resistance. Three additional samples carried the rpoB p.Ser450Leu mutation, a well-characterized resistance mutation included in the GeneXpert MTB/RIF assay. Furthermore, among the six discordant samples detected as isoniazid-sensitive by DST, four carried the katG p.Ser315Thr mutation, associated with high-level isoniazid resistance (Fig. 2 B) ( Fig. 3 ) . We found a significant association between sample type and resistance pattern (p = 0.0446). These findings suggest that the likelihood of detecting drug resistance may differ depending on the type of clinical sample. Lineage, clinical phenotype and drug resistance associations Phylogenetic analysis successfully assigned lineages and sub-lineages to all 117 samples. Overall, four lineages (L1-L4) were detected in EPTB samples. Lineage (East-African Indian) which includes the Delhi/CAS (Central Asian Strain) family was the most predominant (73/117,62.3%), followed by lineage 2 (East Asian) (24/117, 23.3%), lineage 1 (Indo-Oceanic) (22/117, 20.9%), lineage 4 (7/117, 8.0%). These findings are in concordance with the previously reported prevalence of M. tuberculosis lineages from India [ 37 ] (Fig. 4 ). After refining the dataset by excluding rare sample types and underrepresented lineages (< 10), we observed a statistically significant association between sample type, lineage, and drug resistance (Chi-square p = 0.011). Lineage 2 exhibited a higher proportion of drug-resistant isolates (13/24, 54.1%), particularly from CSF samples (9/13, 69.2%), indicating a potential enrichment of resistant strains in extrapulmonary TB presentations involving the central nervous system. In contrast, when all sample types and lineages were included without filtering, the association did not reach statistical significance (p = 0.071). Mixed infections and heteroresistance We observed mixed infections in 8/117 (6.8%) of the samples, the majority of which consisted of lineages 2 and 3 (7/8, 87.5%). One sample was infected with three lineages (L1, L2, L3). Lineage 4 was detected in 7/117 samples. Interestingly, we observed a high prevalence of drug resistance in lineage 2. At higher coverage depth, minority variants can be detected that may go undetected in phenotypic DST or other molecular methods. The presence of heteroresistance may correlate with the mixed infections and, in certain cases, explain the phenotype-genotype discordance. In our study, we detected heteroresistance in four samples: Pus_3, CSF_43, CSF_12, and CSF_8. Table 3 contains the number of reads mapping to mutant and wild-type strains, along with the percentage of heteroresistance in each sample and the corresponding drug. Heteroresistance was significantly higher in mixed infections (p = 0.0139). Of the four samples with heteroresistance, two were infected with multiple strains (CSF_43 with lineages 1, 2, and 3, and CSF_10 with lineages 2 and 3). A lower number of resistant strains against a sensitive background may affect the positivity of resistance strains in culture. However, these are detected in WGS. DISCUSSION Access to comprehensive drug resistance profiles in extrapulmonary tuberculosis is critical for guiding effective treatment regimens. Phenotypic DST is expensive and requires several weeks to provide results. Sequencing-based methods can reduce this turnaround time. However, current molecular and targeted sequencing approaches largely rely on genotype-phenotype associations derived from pulmonary TB. Moreover, the tendency of specific M. tuberculosis lineages to localize in particular extrapulmonary sites, as well as the distribution of drug resistance across these lineages, remains poorly understood. In this study, we performed WGS of M. tuberculosis isolates cultured from seven distinct extrapulmonary sites and compared genotypic data with phenotypic DST results across twelve anti-TB drugs. We determined the phylogenetic lineage of each isolate and explored site-specific correlations between bacterial genotype and clinical phenotype. Additionally, we evaluated the prevalence of drug resistance across various EPTB sample types and investigated whether certain lineages or anatomical sites were associated with elevated resistance levels. We observed drug resistance in 23.9% of isolates based on phenotypic DST and in 30.7% of samples using WGS. These findings are consistent with recently reported trends indicating a rise in drug resistance among EPTB cases [ 38 , 39 ]. We found high concordance (93%) between phenotypic and genotypic resistance profiles, aligning with previous studies reporting concordance rates ranging from 88.9% to 100% [ 40 – 42 ]. Notably, samples discordant with MYCOTBI DST results harbored mutations classified in the WHO mutation catalogue as conferring high-level resistance, suggesting true resistance and highlighting the superior sensitivity of WGS in detecting resistance-associated mutations [ 43 , 44 ]. Additionally, our study observed a higher frequency of drug resistance among EPTB isolates, corroborating prior reports [ 45 ]. There is also limited knowledge regarding the prevalence and clinical significance of mutations associated with resistance to newer anti-TB drugs in EPTB isolates, as these are underrepresented in the WHO mutation catalogue. To address this gap, we included four such drugs that included ofloxacin, cycloserine, PAS, and rifabutin in our analysis. While no phenotypic resistance was detected for these agents by the MYCOTBI assay, WGS revealed mutations associated with ofloxacin resistance in 12 samples and rifabutin resistance in 18 out of 117 samples. These findings underscore the need for expanded phenotype-to-genotype studies to better characterize resistance mutation patterns in EPTB and inform evidence-based treatment strategies. Extensive scientific literature reports a high prevalence of resistance to first-line anti-tubercular drugs. This is likely due to their prolonged and widespread use in TB treatment. In contrast, second-line agents have generally been reserved for drug-resistant cases and are thus associated with lower resistance rates [ 45 , 46 ]. Given the higher frequency of resistance to first-line anti-tubercular drugs, it is essential to identify agents that remain effective in EPTB and exhibit lower rates of resistance-associated mutations. Prior studies have demonstrated that the pharmacokinetic properties of several anti-TB drugs hinder their penetration into extrapulmonary compartments. For example, two first line drugs rifampicin and ethambutol exhibit suboptimal CSF penetration [ 47 ]. The current WHO-recommended TB treatment regimen, which includes 8–12 mg/kg of rifampicin, CSF rifampicin levels often fall below the minimum inhibitory concentration required to effectively eliminate M. tuberculosis [ 2 ]. An increasing number of studies are exploring novel strategies that combine drugs with good penetration with high doses of drugs that typically have poor penetration, aiming to improve treatment outcomes. One study used linezolid and a higher dose of rifampicin to treat TB meningitis and reported optimal levels of linezolid in the CSF [ 48 ]. A clinical study reported significantly reduced mortality in TB meningitis patients treated with high-dose intravenous rifampicin (35%) compared to those receiving standard-dose therapy (65%) [ 11 ]. In contrast, fluoroquinolones show variable CSF penetration, with later-generation compounds such as levofloxacin and moxifloxacin achieving improved distribution [ 49 , 50 ]. Access to individualized drug resistance profiles can facilitate the design of personalized treatment regimens, potentially improving clinical outcomes. As of current scientific consensus, at least nine major phylogenetic lineages of the M. tuberculosis have been identified, with lineages 1 through 4 being the most frequently encountered in global TB studies [ 51 ]. Despite this genetic diversity, current TB diagnostics and treatment regimens do not differentiate between pulmonary and EPTB with respect to lineage, nor do they account for its potential role in drug resistance. However, emerging studies suggest that certain M. tuberculosis lineages may be more prevalent in specific clinical presentations and associated with higher rates of drug resistance [ 13 , 52 ]. Higher drug resistance has been reported in Lineage 2 (Beijing strain) by several studies [ 13 , 53 ] A recent study reported that infection with Lineage 1 was more likely to result in TB osteomyelitis compared to other lineages [ 54 ]. In a large multinational study by Walker and colleagues involving 12,246 patients from three low-incidence and five high-incidence countries, pulmonary TB was significantly more likely in patients infected with lineage 2, 3, or 4 compared to lineage 1. Among pulmonary TB cases, Lineage 1 was associated with a higher risk of cavitary disease relative to Lineages 2 and 4. Conversely, in EPTB, Lineage 1 was more frequently linked to osteomyelitis compared to Lineages 2–4 [ 54 ]. In our study, we observed a significant predominance of Lineage 2 among isolates from CSF samples. Furthermore, we identified a statistically significant association between sample type, lineage, and drug resistance (p = 0.011). Lineage 2 exhibited a high proportion of drug-resistant isolates (13/17, 76.5%), particularly among CSF samples (13/23, 56.5%). These findings support the hypothesis of lineage-specific enrichment in particular anatomical compartments. Further studies with larger sample sizes are needed to validate these associations and assess their clinical implications. Another underexplored factor that may influence the prevalence of drug resistance is the presence of multiple M. tuberculosis strains within a single clinical sample. Co-infection with more than one strain, including drug-resistant variants, has been documented in TB patients [ 55 ]. When resistant strains are present in a minority, they may go undetected by conventional DST, as dominant drug-sensitive strains can outgrow them during culture. Detecting such minority variants is critical for guiding appropriate treatment regimens. In our study, we developed a WGS-based pipeline capable of detecting minority strains and resistance-associated mutations within mixed infections. We found that heteroresistance was significantly more frequent in samples with mixed strain infections (p = 0.0139). These findings suggest that mixed infections substantially increase the likelihood of heteroresistance, which may compromise treatment outcomes. Our results underscore the need to incorporate lineage-specific markers in routine diagnostic workflows to improve the detection and management of complex TB infections. The findings of our study are subject to several limitations. First, we sequenced a very small number of samples, including tissue (n = 8), ileocaecal biopsy (n = 6), synovial fluid (n = 5), and vitreous fluid (n = 1). Further studies with larger sample sizes across these categories are needed to validate whether certain lineages preferentially colonize these sample types. Additionally, our analyses were based on cultured isolates, which may have reduced the observed genetic diversity and led to missed cases of mixed infections. Although we detected mixed infections in eight samples, and these were significantly correlated with heteroresistance, larger studies are needed to confirm these findings. Conclusion This study demonstrates that WGS is a highly effective tool for detecting drug resistance in EPTB, exhibiting a high phenotype-to-genotype concordance of 93.5%. WGS enables the identification of mutations associated with high-level resistance, even in samples that appear phenotypically susceptible, and can detect minority variants often missed by conventional DST. Furthermore, our findings suggest a preferential distribution of certain M. tuberculosis lineages based on clinical phenotype, with some lineages exhibiting a higher frequency of drug resistance. WGS thus offers a reliable alternative to traditional DST, especially in cases of low culture positivity and limited drug penetration at extrapulmonary sites. These insights highlight the potential of WGS to enhance drug resistance detection and inform more precise, effective treatment strategies for EPTB. Abbreviations EPTB Extrapulmonary tuberculosis MDR TB-Multidrug resistant tuberculosis HR TB-Isoniazid resistant tuberculosis RR TB-Rifampicin resistant tuberculosis Pre XDR-Pre-extensively drug resistant tuberculosis WGS Whole genome sequencing CSF Cerebrospinal fluid ICBx Ileocaecal biopsy FNAC Fine needle aspiration cytology SF Synovial fluid VF Vitreous fluid pDST Phenotypic drug susceptibility testing PAS Para-aminosalicylic acid LJ Lowenstein Jensen MGIT Mycobacterial growth indicator tube MIC Minimal inhibitory concentration Declarations Ethics approval and consent to participate All study protocols were approved by PGIMER Institutional Ethics Committee (Reference No. NK/1691/Res/3286). Signed informed consent was obtained from all patients. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publication Not applicable Availability of data and materials WGS data were deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) database with accession PRJNA1273668. Competing interests The authors declare that they have no competing interests Funding This work was supported by the Wellcome Trust/DBT India Alliance Margdarshi Fellowship [grant number IA/M/15/1/502023] awarded to Akhilesh Pandey. Renu Verma is supported by the Ramalingaswami Fellowship, Department of Biotechnology, Government of India [BT/RLF/Re R entry/30/2022]. Authors' contributions KS, RV, and AP conceptualized and designed the study. KS, AS, and MM attended patients and provided clinical data. RV and KS analyzed and interpreted the data and wrote the manuscript. AB processed the samples, performed DNA extraction, and contributed to data analysis. GKM, MR, KV, and JG performed WGS analysis and prepared the figures. ASB and PP contributed to data analysis, figures, and tables. SV and PY also worked on data analysis, tables, and figures. KV and JS supervised the computational team. AG, SKS, MSD, VS, RS, and NS collected clinical samples and done patient follow-up. MS has done data curation, and sample processing. RN did histopathological examination of tissue samples. KS and AP provided input during data analysis and interpretation. All authors reviewed the final manuscript and provided their feedback. Acknowledgements The authors acknowledge Dr. Neeraj Singla, Dr. Ritu Shree, Dr. Ashish Kumar Kakkar, Dr. Apinderpreet Singh, Dr. Sameer Vyas, Dr. Chirag Kamal Ahuja, Dr. Vijeta Patial, Dr. Riya Sharma, Dr. Siddharth Chand, Dr. Yatharth Dixit, Dr. Himanshu, Pratibha Chauhan and all of the technical staff and patients from PGIMER Hospital for their cooperation during the study. References World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024. World Health Organization. WHO operational handbook on tuberculosis. Module 4: Treatment – drug-susceptible tuberculosis treatment. Geneva: WHO; 2022. Ohene SA, Bakker MI, Ojo J, Toonstra A, Awudi D, Klatser P. Extra-pulmonary tuberculosis: a retrospective study of patients in Accra, Ghana. PLoS ONE. 2019;14(1):e0209650. Christensen AS, Roed C, Andersen PH, Andersen ÅB, Obel N. Long-term mortality in patients with pulmonary and extrapulmonary tuberculosis: a Danish nationwide cohort study. Clin Epidemiol 2014 Nov 13:405–21. Boonsarngsuk V, Mangkang K, Santanirand P. Prevalence and risk factors of drug-resistant extrapulmonary tuberculosis. Clin Respir J. 2018;12(6):2101–9. Dusthackeer A, Sekar G, Chidambaram S, Kumar V, Mehta P, Swaminathan S. Drug resistance among extrapulmonary TB patients: Six years experience from a supranational reference laboratory. Indian J Med Res. 2015;142(5):568–74. Maurya AK, Kant S, Nag VL, Kushwaha RA, Dhole TN. Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India. J Postgrad Med. 2012;58(3):185–9. Miiro E, Olum R, Baluku JB. Clinical features, resistance patterns and treatment outcomes of drug-resistant extra-pulmonary tuberculosis: A scoping review. J Clin Tuberculosis Other Mycobact Dis. 2023;33:100390. Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis. 2015;78(2):47. Collins JM, Kipiani M, Jin Y, Sharma AA, Tomalka JA, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, Avaliani Z, Blumberg HM. Pharmacometabolomics in TB meningitis—Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid. PLoS ONE. 2025;20(3):e0315999. Cresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). Wellcome open Res. 2018;3:83. Ford CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013;45(7):784–90. Atavliyeva S, Auganova D, Tarlykov P. Genetic diversity, evolution and drug resistance of Mycobacterium tuberculosis lineage 2. Front Microbiol. 2024;15:1384791. Satti H, McLaughlin MM, Seung KJ, Becerra MC, Keshavjee S. High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2013;17(1):100–6. Ye Y, Hu X, Shi Y, Zhou J, Zhou Y, Song X, Xie Y, Lu X, Wang L, Ying B, Chen X. Clinical features and drug-resistance profile of urinary tuberculosis in south-western China: a cross-sectional study. Medicine. 2016;95(19):e3537. Wang DM, Li QF, Zhu M, Xu YH, Liao Y. Clinical characteristics, common sites and drug resistance profile in culture-confirmed extrapulmonary TB/HIV co-infection patients, Southwest China. J Global Antimicrob Resist. 2022;28:1–7. Schwab TC, Perrig L, Göller PC, De la Hoz FF, Lahousse AP, Minder B, Günther G, Efthimiou O, Omar SV, Egger M, Fenner L. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2024;24(10):1162–76. Gao W, Yang C, Wang T, Guo Y, Zeng Y. Nanopore-based targeted next-generation sequencing of tissue samples for tuberculosis diagnosis. Front Microbiol. 2024;15:1403619. Yu S, Liu N, Xie Z, Zeng Y, Wang H, Wang Q, Li P, Li H, Sun J, Zhu Q, Gao W. Nanopore sequencing for precise detection of Mycobacterium tuberculosis and drug resistance: a retrospective multicenter study in China. J Clin Microbiol. 2025;63(4):e01813–24. Mathys V, Wintjens R, Lefevre P, Bertout J, Singhal A, Kiass M, Kurepina N, Wang XM, Mathema B, Baulard A, Kreiswirth BN. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009;53(5):2100–9. Chen J, Zhang S, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017;72(12):3272–6. Jing W, Pang Y, Zong Z, Wang J, Guo R, Huo F, Jiang G, Ma Y, Huang H, Chu N. Rifabutin resistance associated with double mutations in rpoB gene in Mycobacterium tuberculosis isolates. Front Microbiol. 2017;8:1768. Shi T, Shou F, He Y, Zhou K, Gao W, Nie X, Han M, Liao C, Li T. Whole genome sequencing of drug resistance Mycobacterium tuberculosis from extra-pulmonary sites. Life Sci Alliance. 2023;6(11). Lee J, Armstrong DT, Ssengooba W, Park JA, Yu Y, Mumbowa F, Namaganda C, Mboowa G, Nakayita G, Armakovitch S, Chien G. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first-and second-line drugs. Antimicrob Agents Chemother. 2014;58(1):11–8. Seemann T. Snippy: rapid haploid variant calling and core genome alignment. Available from: https://github.com/tseemann/snippy . Accessed 2 Feb 2015. Jung Y, Han D, BWA-MEME. BWA-MEM emulated with a machine learning approach. Bioinformatics. 2022;38(9):2404–13. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907 [Preprint]. 20 Jul 2012 [cited 2025 Nov 27]. Available from: https://doi.org/10.48550/arXiv.1207.3907 Cingolani P, Platts A, Wang LL, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80–92. Croucher NJ, Page AJ, Connor TR, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res. 2015;43(3):e15. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37(5):1530–4. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 2021;49(W1):W293–6. Verboven L, Phelan J, Heupink TH, Van Rie A. TBProfiler for automated calling of the association with drug resistance of variants in Mycobacterium tuberculosis [published correction appears in. PLoS ONE. 2023;18(10):e0293254. World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd ed. Geneva: WHO; 2023. Wanstrath C, Chacon S, Werner TP, Hyett PJ. GitHub: build and ship software on a single, collaborative platform. Available from: https://github.com/ . Accessed Feb 2008. Reddy TB, Riley R, Wymore F, et al. TB database: an integrated platform for tuberculosis research. Nucleic Acids Res. 2009;37(Database issue):D499–508. Chakravorty S, Simmons AM, Rowneki M, et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio. 2017;8(4):e00812–17. Shanmugam SK, Kumar N, Sembulingam T, et al. Mycobacterium tuberculosis lineages associated with mutations and drug resistance in isolates from India. Microbiol Spectr. 2022;10(3):e0159421. Kant S, Maurya AK, Nag VL, Bajpai J. Rising trend of drug resistance among extrapulmonary. TB North India. 2018;52(suppl 62):PA3681. VidyaRaj CK, Vadakunnel MJ, Mani BR, et al. Prevalence of extrapulmonary tuberculosis and factors influencing successful treatment outcomes among notified cases in South India. Sci Rep. 2025;15(1):8290. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007;45(8):2635–40. Causse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M. Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2008;12(12):1456–60. Huyen MN, Tiemersma EW, Lan NT, et al. Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis. 2010;10:149. Andres S, Hillemann D, Rüsch-Gerdes S, Richter E. Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany. Antimicrob Agents Chemother. 2014;58(1):590–2. Click ES, Kurbatova EV, Alexander H, et al. Isoniazid and rifampin-resistance mutations associated with resistance to second-line drugs and with sputum culture conversion. J Infect Dis. 2020;221(12):2072–82. Forson A, Kudzawu S, Kwara A, Flanigan T. High frequency of first-line anti-tuberculosis drug resistance among persons with chronic pulmonary tuberculosis at a teaching hospital chest clinic. Ghana Med J. 2010;44(2):42–6. Dagne B, Desta K, Fekade R, et al. The epidemiology of first and second-line drug-resistance Mycobacterium tuberculosis complex common species: evidence from selected TB treatment initiating centers in Ethiopia. PLoS ONE. 2021;16(1):e0245687. Abdelgawad N, Wasserman S, Gausi K et al. Population pharmacokinetics of rifampicin in plasma and cerebrospinal fluid in adults with tuberculosis meningitis. J Infect Dis. 2025 Apr 29. Abdelgawad N, Wasserman S, Abdelwahab MT, et al. Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis. J Infect Dis. 2024;229(4):1200–8. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27–35. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90(5):279–92. Bespiatykh D, Bespyatykh J, Mokrousov I, Shitikov E. A comprehensive map of Mycobacterium tuberculosis complex regions of difference. mSphere. 2021;6(4):e0053521. Niemann S, Diel R, Khechinashvili G, et al. Mycobacterium tuberculosis Beijing lineage favors the spread of multidrug-resistant tuberculosis in the Republic of Georgia. J Clin Microbiol. 2010;48(10):3544–50. Hakamata M, Takihara H, Iwamoto T, et al. Higher genome mutation rates of Beijing lineage of Mycobacterium tuberculosis during human infection. Sci Rep. 2020;10(1):17997. Du DH, Geskus RB, Zhao Y, et al. Correction: the effect of M. tuberculosis lineage on clinical phenotype. PLOS Glob Public Health. 2024;4(8):e0003674. Cohen T, van Helden PD, Wilson D, et al. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev. 2012;25(4):708–19. Tables Table 1: Clinical and microbiological characteristics of study cohort Clinical characteristic Total no of patients (n) 117 Male, n (%) 68 (58.1%) Male, age in years, median (IQR) 37 (30.0-48.0) Female, age in years, median (IQR) 33 (24.5-55.5) Sample type Cerebrospinal fluid (CSF), n (%) 40 (34.2%) Pus, n (%) 35 (29.9%) Fine needle aspiration cytology (FNAC), n (%) 22 (18.8%) Tissue, n (%) 8 (6.8%) Ileocecal biopsy (ICBx), n (%) 6 (5.1%) Synovial fluid (SF), n (%) 5 (4.3%) Vitreous fluid (VF), n (%) 1 (0.9%) MYOCTBI profile 1 DS-TB 2 , n (%) 89 (76.1%) HR-TB 3 , n (%) 17 (14.5%) RR-TB 4 , n (%) 2 (1.7%) MDR-TB 5 , n (%) 1 (0.9%) Pre-XDR TB 6 , n (%) 8 (6.8%) MYCOTBI profile was classified according to the latest WHO guidelines 1 , Drug sensitive tuberculosis 2 , Isoniazid-resistant tuberculosis 3 , Rifampicin-resistant tuberculosis 4 , Multidrug-resistant tuberculosis 5 , Pre-extensively drug-resistant tuberculosis 6 ,IQR; Interquartile range Table 2A: Sequencing statistics of 117 M. tuberculosis genomes from EPTB samples Sample type (n) Mean baseQ, median (IQR) Reads mapped to H37Rv (n) H37Rv genome coverage (%) H37Rv genome coverage depth (x) CSF (40) 37.6 (36.8-38.5) 4,958,397 99 (98.8-99.2) 257 (144.3-339.3) Pus (35) 37.4 (36.8-38.3) 6107067 99.2 (98.9-99.3) 320 (199.5-417.5) FNAC (22) 37.3 (37-37.4) 3,408,569 98.9 (98.5-99.1) 143 (111.8-176.8) Tissue (8) 38.5 (38.4-38.5) 2,244,612 99.4 (99.3-99.4) 143 (78-296.8) ICBx (6) 36.9 (36.8-37.1) 3447245 99.4 (99.2-99.5) 141 (124.2-158.2) SF (5) 38.5 (37.3-38.8) 2,707,173 99.4 (99-99.5) 158 (101-230) VF (1) 36.9 3,284,058 98.9 132 Total samples (117) 37.3 (36.8-38.4) 3,992,798 99.1 (98.8-99.3) 201 (122-339) CSF- Cerebrospinal fluid, FNAC - Fine-needle aspiration cytology, ICBx- Ileocaecal biopsy, SF- Synovial fluid, VF-Vitreous fluid, IQR- Interquartile range Table 2B: Drug resistance mutation profiles with the number of samples carrying mutations conferring drug resistance. The samples are classified according to the updated WHO catalog. Samples with resistance (n) Drug affected Gene Mutation WHO classification 11 Rifampicin rpoB p.Ser450Leu AR $ 1 Rifampicin rpoB p.Asp435Val AR $ 4 Rifampicin rpoB p.His445Asn AR $ 2 Rifampicin rpoB rpoB p.Leu452Pro AR $ 20 Isoniazid katG p.Ser315Thr AR $ 16 Isoniazid/Ethionamide fabG1 c.-15C>T AR $ 2 Isoniazid/Ethionamide fabG1 c.-8T>G IR $ 6 Ethionamide ethA c.449_481del IR $ 7 Streptomycin gid c.102delG IR $ 1 Streptomycin gid c.115delC IR $ 4 Streptomycin gid c.137dupA IR $ 4 Streptomycin rpsL p.Lys43Arg AR $ 5 Aminoglycosides* rrs n.1401A>G AR $ 14 Fluoroquinolone # gyrA p.Asp94Gly / p.Asp94Tyr AR $ 1 Ethambutol embB embB p.Gly406Asp AR $ 9 Ethambutol embB p.Met306Leu AR $ 10 Pyrazinamide pncA p.Leu27Pro AR $ 1 Pyrazinamide pncA pncA p.Lys96Thr AR $ 1 Pyrazinamide pncA pncA p.Val139Ala AR $ AR $ - Associated with resistance, IR $ -Associated with resistance interim; # Fluoroquinolone- Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin; *Aminoglycosides- Amikacin, Capreomycin, Kanamycin Table 3: Samples showing heteroresistance based on the reads mapped to both mutant and wild-type strains Sample ID Reference nucleotide Nucleotide position Mutation nucleotide Antibiotic Total reads (Reference: Mutant) Pus_3 C 761139 A Rifampicin 15:231 C 761155 T Rifampicin 245:13 A 781687 G Streptomycin 251:10 A 4247429 G Ethambutol 297:10 C 2155168 G Isoniazid 339:11 CSF_12 T 2288955 G Pyrazinamide 88:281 A 7582 G Fluoroquinolone 77:211 A 4247429 C Ethambutol 73:192 C 2155168 G Isoniazid 108:289 C 1673425 T Isoniazid 72:179 A 761110 T Rifampicin 54:126 A 1472751 G Streptomycin 73:125 CSF_43 A 781687 G Streptomycin 45:23 CSF_8 C 4247863 G Ethambutol 298:18 CSF - Cerebrospinal fluid Additional Declarations No competing interests reported. Supplementary Files Supplementarytable1.xlsx Supplementarytable2.xlsx Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 31 Mar, 2026 Reviews received at journal 28 Feb, 2026 Reviewers agreed at journal 06 Feb, 2026 Reviews received at journal 04 Feb, 2026 Reviewers agreed at journal 04 Feb, 2026 Reviewers agreed at journal 03 Feb, 2026 Reviews received at journal 22 Jan, 2026 Reviews received at journal 29 Dec, 2025 Reviewers agreed at journal 07 Dec, 2025 Reviewers agreed at journal 04 Dec, 2025 Reviewers agreed at journal 02 Dec, 2025 Reviewers invited by journal 02 Dec, 2025 Editor assigned by journal 21 Oct, 2025 Submission checks completed at journal 21 Oct, 2025 First submitted to journal 09 Oct, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7813203","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":554135430,"identity":"0738f790-ed22-44a4-bfea-e654f7d2607a","order_by":0,"name":"Kusum Sharma","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Kusum","middleName":"","lastName":"Sharma","suffix":""},{"id":554135431,"identity":"50c77f6d-d7c1-4dce-8f7b-5cf956c9264a","order_by":1,"name":"Aravind Bandari","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Aravind","middleName":"","lastName":"Bandari","suffix":""},{"id":554135432,"identity":"fdeefcc3-79cb-4395-b1be-42534f53255c","order_by":2,"name":"Gowrang Kasaba Manjunath","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Gowrang","middleName":"Kasaba","lastName":"Manjunath","suffix":""},{"id":554135433,"identity":"56a51ef5-70a3-4642-b3b3-e094bdf28bd7","order_by":3,"name":"Mona Rastogi","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Mona","middleName":"","lastName":"Rastogi","suffix":""},{"id":554135434,"identity":"2e69cd05-70a3-4b9d-9c2f-3333f29ffa61","order_by":4,"name":"Aishwarya S Babu","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Aishwarya","middleName":"S","lastName":"Babu","suffix":""},{"id":554135435,"identity":"ec1323bb-3031-4bff-9c6b-25cb294225ca","order_by":5,"name":"Parthasarathy Ponnusamy","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Parthasarathy","middleName":"","lastName":"Ponnusamy","suffix":""},{"id":554135436,"identity":"d0e346ce-2961-4301-8a7b-2ea353d68cf7","order_by":6,"name":"Shruthi Vasanthaiah","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Shruthi","middleName":"","lastName":"Vasanthaiah","suffix":""},{"id":554135437,"identity":"b4f9e15e-cbfd-4eed-9b8b-575c4bd59c6f","order_by":7,"name":"Karthick Vasudevan","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Karthick","middleName":"","lastName":"Vasudevan","suffix":""},{"id":554135438,"identity":"a7437fdf-dabe-446f-b1d3-5dfdb80bcd1e","order_by":8,"name":"Priyanka Yadav","email":"","orcid":"","institution":"Institute of Bioinformatics","correspondingAuthor":false,"prefix":"","firstName":"Priyanka","middleName":"","lastName":"Yadav","suffix":""},{"id":554135440,"identity":"818307b2-c04b-448b-8cf1-2c5eb9fd19ff","order_by":9,"name":"John George","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"John","middleName":"","lastName":"George","suffix":""},{"id":554135442,"identity":"620a642b-b276-473d-9abf-7fda0050c74e","order_by":10,"name":"Abhishek Kumar","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Abhishek","middleName":"","lastName":"Kumar","suffix":""},{"id":554135444,"identity":"68260541-bb83-4269-bb6a-7707b167365d","order_by":11,"name":"Jyoti Sharma","email":"","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":false,"prefix":"","firstName":"Jyoti","middleName":"","lastName":"Sharma","suffix":""},{"id":554135446,"identity":"b63b514b-a5bf-45fc-bea2-569a3f55b557","order_by":12,"name":"Aman Sharma","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Aman","middleName":"","lastName":"Sharma","suffix":""},{"id":554135447,"identity":"71dc8e83-75d4-454f-9539-c2a96cdb46bb","order_by":13,"name":"Manish Modi","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Manish","middleName":"","lastName":"Modi","suffix":""},{"id":554135448,"identity":"2fa649cb-f6a7-48e7-af6d-a1df9c1a767d","order_by":14,"name":"Amod Gupta","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Amod","middleName":"","lastName":"Gupta","suffix":""},{"id":554135449,"identity":"09341907-5325-48cc-a4e9-715305e7554a","order_by":15,"name":"Ramandeep Singh","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Ramandeep","middleName":"","lastName":"Singh","suffix":""},{"id":554135450,"identity":"39d1d870-df26-48a6-85b7-b0df9b4d8e33","order_by":16,"name":"Saroj K Sinha","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Saroj","middleName":"K","lastName":"Sinha","suffix":""},{"id":554135451,"identity":"6cb47189-1659-4ad3-9ec2-aa35880e4a4b","order_by":17,"name":"M S Dhillon","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"M","middleName":"S","lastName":"Dhillon","suffix":""},{"id":554135452,"identity":"33805763-ff19-4eeb-bcd4-e5bd75914c51","order_by":18,"name":"Megha Sharma","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Megha","middleName":"","lastName":"Sharma","suffix":""},{"id":554135453,"identity":"58b369e7-4796-4b8d-9a66-c77a87d79c53","order_by":19,"name":"Vishal Sharma","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Vishal","middleName":"","lastName":"Sharma","suffix":""},{"id":554135454,"identity":"03f6beb1-a1da-429e-81b7-98a2056cf247","order_by":20,"name":"Ritambhra Nada","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Ritambhra","middleName":"","lastName":"Nada","suffix":""},{"id":554135455,"identity":"935b23e5-de34-4ab2-85e7-f1f85382b165","order_by":21,"name":"Navneet Sharma","email":"","orcid":"","institution":"Post Graduate Institute of Medical Education and Research","correspondingAuthor":false,"prefix":"","firstName":"Navneet","middleName":"","lastName":"Sharma","suffix":""},{"id":554135456,"identity":"28f35d5a-2cb8-48a1-9117-d5611b9a2fc9","order_by":22,"name":"Akhilesh Pandey","email":"","orcid":"","institution":"Institute of Bioinformatics","correspondingAuthor":false,"prefix":"","firstName":"Akhilesh","middleName":"","lastName":"Pandey","suffix":""},{"id":554135457,"identity":"81184815-d328-49a1-a08e-016b42826b92","order_by":23,"name":"Renu Verma","email":"data:image/png;base64,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","orcid":"","institution":"Manipal Academy of Higher Education","correspondingAuthor":true,"prefix":"","firstName":"Renu","middleName":"","lastName":"Verma","suffix":""}],"badges":[],"createdAt":"2025-10-09 05:24:03","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7813203/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7813203/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":97422401,"identity":"7d2ffc2b-a5db-4dff-aa7a-447e11e58d0e","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"doc","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":139264,"visible":true,"origin":"","legend":"","description":"","filename":"MANUSCRIPTwithtables.doc","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/0aee30e63a9ba869bd25d08b.doc"},{"id":97422403,"identity":"766e4c6e-0afe-4dbb-b32e-acd82696d4bc","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"docx","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":15878,"visible":true,"origin":"","legend":"","description":"","filename":"Table1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/0ecb21ec72870cf1093e4344.docx"},{"id":97422402,"identity":"554c8bc7-ef28-4e14-beb9-d2e874328e32","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"docx","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":19409,"visible":true,"origin":"","legend":"","description":"","filename":"Table2.docx","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/5f78723b34563701e4e3a739.docx"},{"id":97667820,"identity":"aeaeee3c-8607-4db7-a8db-993f3265cb54","added_by":"auto","created_at":"2025-12-08 09:24:19","extension":"docx","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":16231,"visible":true,"origin":"","legend":"","description":"","filename":"Table3.docx","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/003f18d4aaab85d1f5cb2b23.docx"},{"id":97422405,"identity":"4cbf8f2b-bbf5-49e7-a97f-58a89ab761ef","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"json","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":21969,"visible":true,"origin":"","legend":"","description":"","filename":"628b769ff51b4b98b6910fba97d4a017.json","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/b86be0ced49c24923c97019e.json"},{"id":97422414,"identity":"a4f074a1-4d5b-43a1-95a2-a0d4beded6b2","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"xlsx","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":78003,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytable1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/0f968501b4d56fea3202afc4.xlsx"},{"id":97667956,"identity":"894306ef-3328-4f77-ab43-0c5f15c501aa","added_by":"auto","created_at":"2025-12-08 09:24:32","extension":"xlsx","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":161967,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytable2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/a83e4db5ac2b308c1d174fad.xlsx"},{"id":97666763,"identity":"42aaf82b-9116-4dd3-b856-df3b3ed1e33d","added_by":"auto","created_at":"2025-12-08 09:22:04","extension":"xml","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":189588,"visible":true,"origin":"","legend":"","description":"","filename":"628b769ff51b4b98b6910fba97d4a0171enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/51dec41c2352e38001004250.xml"},{"id":97422407,"identity":"91f30cb4-7e6f-4e70-a6f5-93957866053c","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"pdf","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":291458,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/6a433bef1abeaf0de8d83f9c.pdf"},{"id":97422406,"identity":"93649046-100b-4540-9767-d951e19a03a1","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"pdf","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":145247,"visible":true,"origin":"","legend":"","description":"","filename":"Figure2.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/dc5e1ab964d0689bc61db73f.pdf"},{"id":97422410,"identity":"baa031a5-68ff-4ea3-9ec1-53a05feceb90","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"pdf","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2098779,"visible":true,"origin":"","legend":"","description":"","filename":"Figure3.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/09c5b0026477dca1b2d57ab8.pdf"},{"id":97422411,"identity":"0dc33157-b902-4a78-a6c0-ed3019db75ae","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"pdf","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":223389,"visible":true,"origin":"","legend":"","description":"","filename":"Figure4.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/38217461267584698f467633.pdf"},{"id":97666280,"identity":"aa6d7444-1f24-45db-83f4-bc6bbe3b2a1f","added_by":"auto","created_at":"2025-12-08 09:20:51","extension":"xml","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":188272,"visible":true,"origin":"","legend":"","description":"","filename":"628b769ff51b4b98b6910fba97d4a0171structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/eeb45292c82dae783305eea5.xml"},{"id":97666628,"identity":"a31f195d-06b4-4e74-8128-fc23ee087d36","added_by":"auto","created_at":"2025-12-08 09:21:44","extension":"html","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":200058,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/5cf1d9c770294426bc924e2b.html"},{"id":97422395,"identity":"75e54e4a-648d-43e7-b6db-ffe28936c24a","added_by":"auto","created_at":"2025-12-04 08:42:57","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":41244,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eWGS coverage depth in EPTB clinical samples. \u003c/strong\u003eThe samples were categorized based on their site of infection and categorized into seven types - cerebrospinal fluid (CSF), fine needle aspiration cytology (FNAC), ileocecal biopsy (ICBx), pus, synovial fluid (SF), tissue and vitreous fluid (VF). Gray dots represent the individual sample in each category. The median genome coverage of the H37Rv strain across all samples was 99.1% (IQR = 99.3–99.8). The overall median coverage depth was 201x (IQR = 122.0–339.5). We observed higher median coverage depth in CSF (median 257.2x) and pus samples (median 320x) compared to other sample types.\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/98f9f40a74f93588e8d6e62d.png"},{"id":97422397,"identity":"ab32834a-ab82-473d-ac9d-d2281cfae9bf","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":75760,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003e(A) MYCOTBI vs WGS resistance profile. \u003c/strong\u003eA comparison of resistance and sensitivity profiles for twelve first-line and second-line anti-TB drugs was conducted using whole genome sequencing (WGS) and drug susceptibility testing (DST). Overall, 93% concordance was observed among the samples. Among the concordant cases (n = 90), 70 were drug-sensitive, 12 were isoniazid-monoresistant, 2 were rifampicin-monoresistant, 1 was MDR-TB, 3 were pre-XDR.\u003cstrong\u003e (B) \u003c/strong\u003eConcordance between whole genome sequencing (WGS) and drug susceptibility testing (DST) results for various anti-tuberculosis drugs.\u003cstrong\u003e \u003c/strong\u003eThe numbers in parentheses indicate the total number of resistant samples for each drug. RIF – Rifampicin, INH – Isoniazid, EMB – Ethambutol, STR – Streptomycin, MXF - Moxifloxacin, OFL – Ofloxacin, AMI – Amikacin, KAN – Kanamycin, ETH – Ethionamide, PAS - Para-amino salicylic acid, CYC – Cycloserine, RFB – Rifabutin.\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/902534acf494798e5b4a4846.png"},{"id":97422396,"identity":"927d7e77-c5d4-46e7-90f1-9a76d8f5413c","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":292748,"visible":true,"origin":"","legend":"\u003cp\u003eThe Circos plot illustrates relationships between various genes and genomic regions associated with antibiotic resistance in \u003cem\u003eM. tuberculosis\u003c/em\u003e. The upper half of the plot is labeled with gene names linked to resistance. Colored connections within the circle represent interactions or correlations between these genes and genomic regions. The dense network of lines underscores the complexity of genetic interactions and the multifactorial nature of antibiotic resistance.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/6654d231c6aea78d12c9aa55.png"},{"id":97667608,"identity":"911c0fc4-aa7a-4680-a8c6-223cd4bf31fc","added_by":"auto","created_at":"2025-12-08 09:23:53","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":82853,"visible":true,"origin":"","legend":"\u003cp\u003eThis phylogenetic tree represents the genetic lineages of the samples, categorized by sample type and their drug resistance profiles for anti-tuberculosis drugs. The adjacent heatmap shows drug resistance patterns, with yellow indicating drug-sensitive samples and black denoting drug-resistant samples.\u003c/p\u003e","description":"","filename":"Figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/92d83fa00a56e038034c5e40.png"},{"id":97677524,"identity":"7855e98f-311f-48cd-8407-8092d33733e8","added_by":"auto","created_at":"2025-12-08 09:53:23","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1979471,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/21631f92-c69d-43ef-9808-077b5e21cc8a.pdf"},{"id":97422399,"identity":"e4a5158b-e6f2-47ea-a520-d86c90fc26ab","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":78003,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytable1.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/7f75b141f3bf01b78d3fe3cc.xlsx"},{"id":97422400,"identity":"a4bbc6f8-9dbf-4979-a659-d49b3422b047","added_by":"auto","created_at":"2025-12-04 08:42:58","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":161967,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytable2.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-7813203/v1/906bbc02e33af808a4e81939.xlsx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Genomic insights into extrapulmonary tuberculosis reveal enrichment of lineage 2 with high drug resistance in specific clinical phenotypes","fulltext":[{"header":"BACKGROUND","content":"\u003cp\u003eEPTB accounts for 15\u0026ndash;20% of the global TB burden [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e] and is associated with high mortality, poor treatment outcomes, and increased relapse rates [\u003cspan additionalcitationids=\"CR3 CR4\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Recent studies have reported rising drug resistance among EPTB patients, complicating diagnosis and disease management [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Drug resistance in EPTB ranges from 10\u0026ndash;20%, with up to 40% resistance reported against first-line anti-TB drugs [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eDespite these challenges, current guidelines largely recommend uniform treatment regimens for pulmonary TB and EPTB [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. However, anti-TB drugs show lower penetration at certain extrapulmonary sites, such as CSF, leading to subtherapeutic levels and possible treatment failure [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In such cases, poor drug exposure rather than microbial resistance may contribute to adverse outcomes. Dose adjustments based on the clinical phenotype and resistance profile may improve outcomes [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eCompounding these challenges, clinicians often lack complete resistance profiles to distinguish between pharmacokinetic failure and true resistance due to challenges in detecting drug resistance in EPTB samples. In addition, \u003cem\u003eM. tuberculosis\u003c/em\u003e lineage influences disease severity, transmission dynamics, and resistance development [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. Some lineages exhibit higher virulence, increased drug resistance, and stronger associations with specific anatomical sites in pulmonary TB [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e], yet their role in EPTB remains underexplored.\u003c/p\u003e\u003cp\u003eDiagnosing drug resistance in EPTB is further complicated by its paucibacillary nature and low culture positivity [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Resistance is frequently suspected only after clinical non-response [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. The WHO recommends molecular assays like GeneXpert MTB/RIF and GeneXpert MTB/RIF Ultra for rapid detection of \u003cem\u003eM. tuberculosis\u003c/em\u003e and rifampicin resistance, though these tools detect limited mutations [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Studies have identified resistance to both first- and second-line drugs in EPTB [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eTargeted sequencing platforms, informed by the WHO mutation catalogue, enable rapid, culture-free detection of resistance mutations and lineage assignment [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. However, these panels are primarily developed using data from pulmonary TB [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Furthermore, phenotypic-genotype data for drugs like ofloxacin, cycloserine, para-aminosalicylic acid (PAS), and rifabutin are not included in the current WHO catalogue, despite evidence of resistance-linked mutations [\u003cspan additionalcitationids=\"CR21\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eIn this study, we performed WGS of \u003cem\u003eM. tuberculosis\u003c/em\u003e isolates from seven extrapulmonary sites and compared genotypic resistance with MYCOTBI phenotypic DST across twelve anti-TB drugs. We also examined heteroresistance, mixed infections, and associations between lineage, drug resistance, and clinical phenotype.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003ePatient enrollment and ethical statement\u003c/h2\u003e\u003cp\u003eWe used \u003cem\u003eM. tuberculosis\u003c/em\u003e positive culture isolates from extrapulmonary sites collected between 2014\u0026ndash;2020 at the Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The study was approved by the PGIMER Institutional Ethics Committee (Reference No. NK/1691/Res/3286). All participants were aged 18 years or older and provided written consent before the initiation of the study.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eSample processing and DNA extraction\u003c/h3\u003e\n\u003cp\u003eA total of 117 \u003cem\u003eM. tuberculosis\u003c/em\u003e positive cultures were collected from seven extrapulmonary sites. These included CSF (n\u0026thinsp;=\u0026thinsp;40), pus (n\u0026thinsp;=\u0026thinsp;35), fine-needle aspiration cytology (FNAC) (n\u0026thinsp;=\u0026thinsp;22), tissue (n\u0026thinsp;=\u0026thinsp;8), ileocaecal biopsy (ICBx) (n\u0026thinsp;=\u0026thinsp;6), synovial fluid (SF) (n\u0026thinsp;=\u0026thinsp;5) and vitreous fluid (VF) (n\u0026thinsp;=\u0026thinsp;1). All the isolates were processed as per the standard protocol described previously [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. The samples were inoculated to Mycobacteria Growth Indicator Tube (MGIT) and solid culture Lowenstein-Jensen (LJ) slants (Difco Lowenstein Medium Base No. 244420) and incubated at 37˚C for eight weeks. The cultures were subsequently tested using commercially available SD BIOLINE TB Ag MPT64 rapid kit to rule out non-tuberculous mycobacteria. DNA was extracted using QIAamp DNA Mini Kit, according to the manufacturer\u0026rsquo;s instructions, eluted in 50\u0026micro;l nuclease-free water and stored at -20\u0026deg;C until use.\u003c/p\u003e\n\u003ch3\u003eSensititre MYCOTB assay\u003c/h3\u003e\n\u003cp\u003eWe performed minimum inhibitory concentration (MIC) based phenotypic DST using MYCOTBI sensititre plates (Sensititre MYCOTB assay, Thermo Fisher Scientific, USA) on all culture-positive samples (n\u0026thinsp;=\u0026thinsp;117) according to the manufacturer's instructions. The MYCOTBI plates are pre-coated with twelve standardized drug concentrations, including isoniazid, rifampicin, ethambutol, streptomycin, moxifloxacin, ofloxacin, cycloserine, PAS, rifabutin, amikacin, kanamycin, and ethionamide [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e\u003cp\u003eFor MYCOTBI testing, mycobacterial strains isolated from extrapulmonary regions were subcultured onto LJ slants (Difco Lowenstein Medium Base No. 244420). Colonies with bacterial growth were added to 200 \u0026micro;l of saline-Tween 80 solution (Trek Diagnostic Systems) containing 0.5 mm silica beads and vortexed for 30 seconds. The colony suspension was allowed to settle for 10 minutes, and the turbidity of the sample was adjusted to match the 0.5 McFarland standard. A total of 100 \u0026micro;l of the adjusted saline suspension was transferred to 11 ml of Middlebrook 7H9 broth containing oleic acid-albumin-dextrose-catalase (Trek Diagnostic Systems) and mixed thoroughly. Then, 100 \u0026micro;l of the suspension was inoculated into each well of the MYCOTBI plate. The plates were sealed and incubated at 37\u0026deg;C in a 5% CO₂ atmosphere. Plates were monitored on days 7, 14, 21, and 28 post-inoculation using a manual plate reader with data management software (Vizion System, TREK Diagnostics). If the MIC value of a drug was higher than its critical concentration, the strain was classified as resistant; if it was equal to or below the critical concentration, the strain was classified as sensitive. Each MYCOTBI plate was independently read, interpreted, and recorded by two readers to ensure agreement. For phenotype-to-genotype comparisons of drug resistance, the readings from day 28 were considered final.\u003c/p\u003e\n\u003ch3\u003eLibrary preparation\u003c/h3\u003e\n\u003cp\u003eGenomic DNA was quantified using the Qubit fluorometric method. DNA samples were prepared for library construction using the Twist EF Library Prep Kit for Illumina (Cat#100572). Initially, DNA was fragmented to the desired size, followed by end-repair and 3\u0026rsquo; mono-adenylation in a single enzymatic reaction. Adapters were then ligated using a T4 DNA ligase-based reaction. Post-ligation, the libraries were PCR-amplified with unique barcoded primers (Twist Unique Dual Index Primer Set A, Cat#101308) for sample multiplexing. Fragment distribution was assessed using the Agilent 5300 Fragment Analyzer System. The clustered libraries were sequenced on the Illumina HiSeq XTen platform to generate 150 bp paired-end reads.\u003c/p\u003e\n\u003ch3\u003eVariant mapping, annotation and phylogenetic analysis\u003c/h3\u003e\n\u003cp\u003eWe used Snippy [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e] for whole-genome alignment to the \u003cem\u003eM. tuberculosis\u003c/em\u003e reference genome H37Rv (Acc: NC000962) and variant calling. Snippy is a freely available Perl-based tool capable of identifying both single nucleotide polymorphisms (SNPs) and indels. It leverages BWA-MEM [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e] and FreeBayes [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. We ran Snippy with default parameters, which have previously been shown to produce high-quality variant calls. Variants were annotated using SnpEff [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e] with the H37Rv reference genome. Snippy-core was employed to generate core-alignment files. Gubbins v2.4.1 [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e] was used to produce an alignment file with recombinant sites masked. A maximum-likelihood phylogenetic tree based on the core SNPs was constructed using IQ-TREE2 [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e], with 1000 ultrafast bootstrap iterations and the GTR model. The generated phylogenetic tree was visualized and annotated using iTOL [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003eDrug Resistance and lineage identification:\u003c/h2\u003e\u003cp\u003eWe used TBProfiler v6.5.0 to detect drug resistance and identify lineages [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. TBProfiler aligns reads to the H37Rv reference genome using Bowtie2, BWA, or Minimap2, and then calls variants with BCFtools. After variant calling, the collate function extracts drug-resistance mutations and lineage information using a database of drug resistance mutations and lineage markers hosted on the TBDB repository [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. Additionally, the identified mutations associated with drug resistance were compared against the WHO catalogue [\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e] to distinguish between mutations linked to drug resistance and those not associated with it.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eHeteroresistance detection\u003c/h3\u003e\n\u003cp\u003eWe used an inhouse customized Python scripts [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e] to detect heteroresistance in \u003cem\u003eM. tuberculosis\u003c/em\u003e. Initially, we curated a database of mutations associated with antibiotic resistance [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]. Using the samtools mpileup command, we generated pileup files for specific genomic regions of interest from a sorted BAM file aligned to the reference genome of \u003cem\u003eM. tuberculosis H37Rv\u003c/em\u003e. We then parsed these pileup files to calculate nucleotide frequencies at the mutation sites. Further, we processed each mutation entry by extracting the reference and mutant nucleotide frequencies, as well as the total read counts, to determine the presence and extent of heteroresistance. We used a minimum 10 reads cutoff to consider a mutation as true positive for heteroresistance detection. The calculated frequencies and read counts were subsequently compiled into an Excel report, sorted by mutant frequency to highlight significant mutations.\u003c/p\u003e\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\u003ch2\u003eStatistical analysis\u003c/h2\u003e\u003cp\u003eA Chi-square test was conducted to assess the presence of a significant association between sample type and drug resistance. Only sample types with a sample size of 10 or greater were included in the analysis. We also performed Chi-square test to determine if there was any significant correlation between sample type, lineage, and drug resistance. We performed McNemar\u0026rsquo;s test to compare the diagnostic performance of MYCOTBI phenotypic drug susceptibility testing with whole genome sequencing, considering WGS as the reference standard. All data analysis were performed in R.\u003c/p\u003e\u003c/div\u003e"},{"header":"RESULTS","content":"\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\n \u003ch2\u003eStudy participants and sample characteristics\u003c/h2\u003e\n \u003cp\u003eOf the 117 individuals with active EPTB whose positive culture isolates were used for the study, 58% (68/117) were male (median age\u0026thinsp;=\u0026thinsp;37 years; IQR\u0026thinsp;=\u0026thinsp;30\u0026ndash;48). The median age of female participants was 33 years (IQR\u0026thinsp;=\u0026thinsp;24.5\u0026ndash;55.5). Samples were classified based on the site of infection, including CSF (40/117, 34.2%), pus (35/117, 29.9%), FNAC (22/117, 18.8%), tissue (8/117, 6.8%), ICBx (6/117, 5.1%), SF (5/117, 4.3%), and VF (1/117, 0.9%). The clinical and microbiological characteristics of the study cohort are summarized in Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\n \u003ch2\u003eMYCOTBI phenotypic drug susceptibility\u003c/h2\u003e\n \u003cp\u003eOf the seven different sample types, resistance to at least one drug tested in the MYCOTBI phenotypic drug susceptibility assay was observed in 28/117 (23.9%) \u003cem\u003eM. tuberculosis\u003c/em\u003e isolates. These included samples from four sites, CSF (16/28, 57.1%), pus (8/28, 28.5%), synovial fluid (SF, 1/28, 3.5%), and FNAC (3/28, 10.7%). Based on MYCOTBI phenotypic DST, samples were identified as isoniazid-resistant TB (HR-TB, 17/117, 14.5%), rifampicin-resistant TB (RR-TB, 2/117, 1.7%), multidrug-resistant TB (MDR-TB, 1/117, 0.9%), and pre-extensively drug-resistant TB (Pre-XDR-TB, 8/117, 6.8%). We observed high levels of drug resistance to first-line anti-TB drugs. Isoniazid mono-resistance was the most prevalent (17/28, 60.7%), followed by resistance to ethambutol (13/117, 11.1%), rifampicin (11/117, 9.4%), and streptomycin (11/117, 9.4%). No resistance was detected to ofloxacin, cycloserine, PAS, or rifabutin in phenotypic drug susceptibility testing. (\u003cstrong\u003eSupplementary table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e\u003c/strong\u003e).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e\n \u003ch2\u003eWhole genome sequencing and genotypic drug resistance\u003c/h2\u003e\n \u003cp\u003eAll samples (n\u0026thinsp;=\u0026thinsp;117) met the minimum quality criteria (Phred score\u0026thinsp;\u0026ge;\u0026thinsp;20, coverage depth\u0026thinsp;\u0026ge;\u0026thinsp;50x). The median H37Rv genome coverage across all samples was 99.1% (IQR\u0026thinsp;=\u0026thinsp;99.3\u0026ndash;99.8). The overall median coverage depth was 201x (IQR\u0026thinsp;=\u0026thinsp;122.0\u0026ndash;339.5). A summary of sequencing statistics is provided in Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eA. We observed higher median coverage depth in CSF (median 257.2x) and pus samples (median 320x) compared to other sample types (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e\n \u003cp\u003eWe compared the variant calling data from WGS with the most recent version of the WHO mutation catalogue to identify drug resistance-associated mutations [\u003cspan class=\"CitationRef\"\u003e33\u003c/span\u003e]. Mutation profiles for four drugs included in the MYCOTBI sensititre panel namely ofloxacin, cycloserine, PAS, and rifabutin are not present in the WHO mutation catalogue. However, substantial literature evidence supports the existence of drug resistance-associated mutations for these drugs [\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e]. These mutations are incorporated into the widely used TBProfiler platform [\u003cspan class=\"CitationRef\"\u003e32\u003c/span\u003e]. We used the mutation profiles derived from TBProfiler for these drugs to assess genotype-to-phenotype concordance. Based on WGS analysis, 36/117 (30.7%) samples exhibited mutations associated with at least one drug included in the MYCOTBI test panel (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eA, \u003cstrong\u003eSupplementary Table\u0026nbsp;2\u003c/strong\u003e). Seventeen unique mutations were identified in eight genes (\u003cem\u003eembA, embB, fabG1, katG, gyrA, pncA, rpoB, rrs\u003c/em\u003e). The \u003cem\u003ekatG\u003c/em\u003e p.Ser315Thr mutation, which confers high-level resistance to isoniazid, was detected in 21/117 (17.9%) samples. Rifampicin resistance associated mutations were detected in 18/117 (15.3%) samples. These mutations are included in the GeneXpert MTB/RIF Ultra point-of-care test and are known to confer high-level rifampicin resistance [\u003cspan class=\"CitationRef\"\u003e36\u003c/span\u003e]. The \u003cem\u003erpoB\u003c/em\u003e p.Ser450Leu mutation was the most prevalent, detected in 11/18 samples (61.1%), followed by \u003cem\u003erpoB\u003c/em\u003e p.His445Asn in 4/18 samples (22.2%), and \u003cem\u003erpoB\u003c/em\u003e p.Leu452Pro in 2/18 samples (11.1%). These mutations occur within the rifampicin resistance-determining region (RRDR) of the \u003cem\u003erpoB\u003c/em\u003e gene and are associated with high-level rifampicin resistance. Of the four drugs for which mutation profiles are not yet fully incorporated in the current WHO mutation catalogue, we detected mutations associated with ofloxacin resistance in 12 samples and rifabutin resistance in 18 out of 117 samples. According to WHO\u0026rsquo;s 2021 catalogue of mutations in \u003cem\u003eM. tuberculosis\u003c/em\u003e, the p.Asp435Val mutation is classified as associated with rifampicin resistance but does not always confer resistance to rifabutin. The distribution of mutations across various samples is shown in Table \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eB.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\n \u003ch2\u003ePhenotype-genotype agreement\u003c/h2\u003e\n \u003cp\u003eFor the phenotype-to-genotype sensitivity analysis, we considered only those mutations listed in the WHO mutation catalogue as strongly associated with drug resistance. Based on this, WGS was selected as the reference standard to evaluate the sensitivity of the MYCOTBI drug DST for detecting resistance. A statistically significant difference in sensitivity between MYCOTBI DST and WGS was observed (McNemar\u0026rsquo;s p\u0026thinsp;=\u0026thinsp;0.039). The MYCOTBI DST correctly identified 77.1% of resistant cases and 98.8% of sensitive cases as determined by WGS. These findings suggest that while MYCOTBI DST demonstrates high specificity (i.e., few false positives), it is less sensitive, missing approximately 23% of drug-resistant cases identified by WGS. Streptomycin exhibited the highest discordance between DST and WGS, with a difference observed in 22 cases. Additionally, two samples detected as rifampicin-sensitive by DST harbored \u003cem\u003erpoB\u003c/em\u003e p.His445Asn and \u003cem\u003erpoB\u003c/em\u003e p.Leu452Pro mutations, both known to confer high-level rifampicin resistance. Three additional samples carried the \u003cem\u003erpoB\u003c/em\u003e p.Ser450Leu mutation, a well-characterized resistance mutation included in the GeneXpert MTB/RIF assay. Furthermore, among the six discordant samples detected as isoniazid-sensitive by DST, four carried the \u003cem\u003ekatG\u003c/em\u003e p.Ser315Thr mutation, associated with high-level isoniazid resistance (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eB) \u003cstrong\u003e(\u003c/strong\u003eFig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e\u003cstrong\u003e)\u003c/strong\u003e. We found a significant association between sample type and resistance pattern (p\u0026thinsp;=\u0026thinsp;0.0446). These findings suggest that the likelihood of detecting drug resistance may differ depending on the type of clinical sample.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\n \u003ch2\u003eLineage, clinical phenotype and drug resistance associations\u003c/h2\u003e\n \u003cp\u003ePhylogenetic analysis successfully assigned lineages and sub-lineages to all 117 samples. Overall, four lineages (L1-L4) were detected in EPTB samples. Lineage (East-African Indian) which includes the Delhi/CAS (Central Asian Strain) family was the most predominant (73/117,62.3%), followed by lineage 2 (East Asian) (24/117, 23.3%), lineage 1 (Indo-Oceanic) (22/117, 20.9%), lineage 4 (7/117, 8.0%). These findings are in concordance with the previously reported prevalence of \u003cem\u003eM. tuberculosis\u003c/em\u003e lineages from India [\u003cspan class=\"CitationRef\"\u003e37\u003c/span\u003e] (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003e). After refining the dataset by excluding rare sample types and underrepresented lineages (\u0026lt;\u0026thinsp;10), we observed a statistically significant association between sample type, lineage, and drug resistance (Chi-square p\u0026thinsp;=\u0026thinsp;0.011). Lineage 2 exhibited a higher proportion of drug-resistant isolates (13/24, 54.1%), particularly from CSF samples (9/13, 69.2%), indicating a potential enrichment of resistant strains in extrapulmonary TB presentations involving the central nervous system. In contrast, when all sample types and lineages were included without filtering, the association did not reach statistical significance (p\u0026thinsp;=\u0026thinsp;0.071).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\n \u003ch2\u003eMixed infections and heteroresistance\u003c/h2\u003e\n \u003cp\u003eWe observed mixed infections in 8/117 (6.8%) of the samples, the majority of which consisted of lineages 2 and 3 (7/8, 87.5%). One sample was infected with three lineages (L1, L2, L3). Lineage 4 was detected in 7/117 samples. Interestingly, we observed a high prevalence of drug resistance in lineage 2. At higher coverage depth, minority variants can be detected that may go undetected in phenotypic DST or other molecular methods. The presence of heteroresistance may correlate with the mixed infections and, in certain cases, explain the phenotype-genotype discordance. In our study, we detected heteroresistance in four samples: Pus_3, CSF_43, CSF_12, and CSF_8. Table \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e contains the number of reads mapping to mutant and wild-type strains, along with the percentage of heteroresistance in each sample and the corresponding drug. Heteroresistance was significantly higher in mixed infections (p\u0026thinsp;=\u0026thinsp;0.0139). Of the four samples with heteroresistance, two were infected with multiple strains (CSF_43 with lineages 1, 2, and 3, and CSF_10 with lineages 2 and 3). A lower number of resistant strains against a sensitive background may affect the positivity of resistance strains in culture. However, these are detected in WGS.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eAccess to comprehensive drug resistance profiles in extrapulmonary tuberculosis is critical for guiding effective treatment regimens. Phenotypic DST is expensive and requires several weeks to provide results. Sequencing-based methods can reduce this turnaround time. However, current molecular and targeted sequencing approaches largely rely on genotype-phenotype associations derived from pulmonary TB. Moreover, the tendency of specific \u003cem\u003eM. tuberculosis\u003c/em\u003e lineages to localize in particular extrapulmonary sites, as well as the distribution of drug resistance across these lineages, remains poorly understood. In this study, we performed WGS of \u003cem\u003eM. tuberculosis\u003c/em\u003e isolates cultured from seven distinct extrapulmonary sites and compared genotypic data with phenotypic DST results across twelve anti-TB drugs. We determined the phylogenetic lineage of each isolate and explored site-specific correlations between bacterial genotype and clinical phenotype. Additionally, we evaluated the prevalence of drug resistance across various EPTB sample types and investigated whether certain lineages or anatomical sites were associated with elevated resistance levels.\u003c/p\u003e\u003cp\u003eWe observed drug resistance in 23.9% of isolates based on phenotypic DST and in 30.7% of samples using WGS. These findings are consistent with recently reported trends indicating a rise in drug resistance among EPTB cases [\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e, \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. We found high concordance (93%) between phenotypic and genotypic resistance profiles, aligning with previous studies reporting concordance rates ranging from 88.9% to 100% [\u003cspan additionalcitationids=\"CR41\" citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. Notably, samples discordant with MYCOTBI DST results harbored mutations classified in the WHO mutation catalogue as conferring high-level resistance, suggesting true resistance and highlighting the superior sensitivity of WGS in detecting resistance-associated mutations [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e]. Additionally, our study observed a higher frequency of drug resistance among EPTB isolates, corroborating prior reports [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e]. There is also limited knowledge regarding the prevalence and clinical significance of mutations associated with resistance to newer anti-TB drugs in EPTB isolates, as these are underrepresented in the WHO mutation catalogue. To address this gap, we included four such drugs that included ofloxacin, cycloserine, PAS, and rifabutin in our analysis. While no phenotypic resistance was detected for these agents by the MYCOTBI assay, WGS revealed mutations associated with ofloxacin resistance in 12 samples and rifabutin resistance in 18 out of 117 samples. These findings underscore the need for expanded phenotype-to-genotype studies to better characterize resistance mutation patterns in EPTB and inform evidence-based treatment strategies.\u003c/p\u003e\u003cp\u003eExtensive scientific literature reports a high prevalence of resistance to first-line anti-tubercular drugs. This is likely due to their prolonged and widespread use in TB treatment. In contrast, second-line agents have generally been reserved for drug-resistant cases and are thus associated with lower resistance rates [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e]. Given the higher frequency of resistance to first-line anti-tubercular drugs, it is essential to identify agents that remain effective in EPTB and exhibit lower rates of resistance-associated mutations. Prior studies have demonstrated that the pharmacokinetic properties of several anti-TB drugs hinder their penetration into extrapulmonary compartments. For example, two first line drugs rifampicin and ethambutol exhibit suboptimal CSF penetration [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. The current WHO-recommended TB treatment regimen, which includes 8\u0026ndash;12 mg/kg of rifampicin, CSF rifampicin levels often fall below the minimum inhibitory concentration required to effectively eliminate \u003cem\u003eM. tuberculosis\u003c/em\u003e [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. An increasing number of studies are exploring novel strategies that combine drugs with good penetration with high doses of drugs that typically have poor penetration, aiming to improve treatment outcomes. One study used linezolid and a higher dose of rifampicin to treat TB meningitis and reported optimal levels of linezolid in the CSF [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. A clinical study reported significantly reduced mortality in TB meningitis patients treated with high-dose intravenous rifampicin (35%) compared to those receiving standard-dose therapy (65%) [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. In contrast, fluoroquinolones show variable CSF penetration, with later-generation compounds such as levofloxacin and moxifloxacin achieving improved distribution [\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e]. Access to individualized drug resistance profiles can facilitate the design of personalized treatment regimens, potentially improving clinical outcomes.\u003c/p\u003e\u003cp\u003eAs of current scientific consensus, at least nine major phylogenetic lineages of the \u003cem\u003eM. tuberculosis\u003c/em\u003e have been identified, with lineages 1 through 4 being the most frequently encountered in global TB studies [\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e]. Despite this genetic diversity, current TB diagnostics and treatment regimens do not differentiate between pulmonary and EPTB with respect to lineage, nor do they account for its potential role in drug resistance. However, emerging studies suggest that certain \u003cem\u003eM. tuberculosis\u003c/em\u003e lineages may be more prevalent in specific clinical presentations and associated with higher rates of drug resistance [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e]. Higher drug resistance has been reported in Lineage 2 (Beijing strain) by several studies [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e] A recent study reported that infection with Lineage 1 was more likely to result in TB osteomyelitis compared to other lineages [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. In a large multinational study by Walker and colleagues involving 12,246 patients from three low-incidence and five high-incidence countries, pulmonary TB was significantly more likely in patients infected with lineage 2, 3, or 4 compared to lineage 1. Among pulmonary TB cases, Lineage 1 was associated with a higher risk of cavitary disease relative to Lineages 2 and 4. Conversely, in EPTB, Lineage 1 was more frequently linked to osteomyelitis compared to Lineages 2\u0026ndash;4 [\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e]. In our study, we observed a significant predominance of Lineage 2 among isolates from CSF samples. Furthermore, we identified a statistically significant association between sample type, lineage, and drug resistance (p\u0026thinsp;=\u0026thinsp;0.011). Lineage 2 exhibited a high proportion of drug-resistant isolates (13/17, 76.5%), particularly among CSF samples (13/23, 56.5%). These findings support the hypothesis of lineage-specific enrichment in particular anatomical compartments. Further studies with larger sample sizes are needed to validate these associations and assess their clinical implications.\u003c/p\u003e\u003cp\u003eAnother underexplored factor that may influence the prevalence of drug resistance is the presence of multiple \u003cem\u003eM. tuberculosis\u003c/em\u003e strains within a single clinical sample. Co-infection with more than one strain, including drug-resistant variants, has been documented in TB patients [\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e]. When resistant strains are present in a minority, they may go undetected by conventional DST, as dominant drug-sensitive strains can outgrow them during culture. Detecting such minority variants is critical for guiding appropriate treatment regimens.\u003c/p\u003e\u003cp\u003eIn our study, we developed a WGS-based pipeline capable of detecting minority strains and resistance-associated mutations within mixed infections. We found that heteroresistance was significantly more frequent in samples with mixed strain infections (p\u0026thinsp;=\u0026thinsp;0.0139). These findings suggest that mixed infections substantially increase the likelihood of heteroresistance, which may compromise treatment outcomes. Our results underscore the need to incorporate lineage-specific markers in routine diagnostic workflows to improve the detection and management of complex TB infections.\u003c/p\u003e\u003cp\u003eThe findings of our study are subject to several limitations. First, we sequenced a very small number of samples, including tissue (n\u0026thinsp;=\u0026thinsp;8), ileocaecal biopsy (n\u0026thinsp;=\u0026thinsp;6), synovial fluid (n\u0026thinsp;=\u0026thinsp;5), and vitreous fluid (n\u0026thinsp;=\u0026thinsp;1). Further studies with larger sample sizes across these categories are needed to validate whether certain lineages preferentially colonize these sample types. Additionally, our analyses were based on cultured isolates, which may have reduced the observed genetic diversity and led to missed cases of mixed infections. Although we detected mixed infections in eight samples, and these were significantly correlated with heteroresistance, larger studies are needed to confirm these findings.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThis study demonstrates that WGS is a highly effective tool for detecting drug resistance in EPTB, exhibiting a high phenotype-to-genotype concordance of 93.5%. WGS enables the identification of mutations associated with high-level resistance, even in samples that appear phenotypically susceptible, and can detect minority variants often missed by conventional DST. Furthermore, our findings suggest a preferential distribution of certain \u003cem\u003eM. tuberculosis\u003c/em\u003e lineages based on clinical phenotype, with some lineages exhibiting a higher frequency of drug resistance. WGS thus offers a reliable alternative to traditional DST, especially in cases of low culture positivity and limited drug penetration at extrapulmonary sites. These insights highlight the potential of WGS to enhance drug resistance detection and inform more precise, effective treatment strategies for EPTB.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eEPTB\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eExtrapulmonary tuberculosis\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eMDR\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eTB-Multidrug resistant tuberculosis\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eHR\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eTB-Isoniazid resistant tuberculosis\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eRR\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eTB-Rifampicin resistant tuberculosis\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003ePre\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eXDR-Pre-extensively drug resistant tuberculosis\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eWGS\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eWhole genome sequencing\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eCSF\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eCerebrospinal fluid\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eICBx\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eIleocaecal biopsy\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eFNAC\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eFine needle aspiration cytology\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eSF\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eSynovial fluid\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eVF\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eVitreous fluid\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003epDST\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003ePhenotypic drug susceptibility testing\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003ePAS\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003ePara-aminosalicylic acid\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eLJ\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eLowenstein Jensen\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eMGIT\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eMycobacterial growth indicator tube\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv class=\"DefinitionListEntry\"\u003e\u003cdiv class=\"Term\"\u003eMIC\u003c/div\u003e\u003cdiv class=\"Description\"\u003e\u003cp\u003eMinimal inhibitory concentration\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll study protocols were approved by PGIMER Institutional Ethics Committee (Reference No. NK/1691/Res/3286). Signed informed consent was obtained from all patients. All methods were carried out in accordance with relevant guidelines and regulations.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWGS data were deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) database with accession PRJNA1273668.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the Wellcome Trust/DBT India Alliance Margdarshi Fellowship [grant number IA/M/15/1/502023] awarded to Akhilesh Pandey.\u0026nbsp;Renu Verma is supported by the Ramalingaswami Fellowship, Department of Biotechnology, \u0026nbsp;Government of India [BT/RLF/Re R entry/30/2022].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKS, RV, and AP conceptualized and designed the study. KS, AS, and MM attended patients and provided clinical data. RV and KS analyzed and interpreted the data and wrote the manuscript. AB processed the samples, performed DNA extraction, and contributed to data analysis. GKM, MR, KV, and JG performed WGS analysis and prepared the figures. ASB and PP contributed to data analysis, figures, and tables. SV and PY also worked on data analysis, tables, and figures. KV and JS supervised the computational team. AG, SKS, MSD, VS, RS, and NS collected clinical samples and done patient follow-up. MS has done data curation, and sample processing. RN did histopathological examination of tissue samples. KS and AP provided input during data analysis and interpretation. All authors reviewed the final manuscript and provided their feedback.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors acknowledge Dr. Neeraj Singla, Dr. Ritu Shree, Dr. Ashish Kumar Kakkar, Dr. Apinderpreet Singh, Dr. Sameer Vyas, Dr. Chirag Kamal Ahuja, Dr. Vijeta Patial, Dr. Riya Sharma, Dr. Siddharth Chand, Dr. Yatharth Dixit, Dr. Himanshu, Pratibha Chauhan and all of the technical staff and patients from PGIMER Hospital for their cooperation during the study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eWorld Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWorld Health Organization. WHO operational handbook on tuberculosis. Module 4: Treatment \u0026ndash; drug-susceptible tuberculosis treatment. Geneva: WHO; 2022.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eOhene SA, Bakker MI, Ojo J, Toonstra A, Awudi D, Klatser P. Extra-pulmonary tuberculosis: a retrospective study of patients in Accra, Ghana. PLoS ONE. 2019;14(1):e0209650.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChristensen AS, Roed C, Andersen PH, Andersen \u0026Aring;B, Obel N. Long-term mortality in patients with pulmonary and extrapulmonary tuberculosis: a Danish nationwide cohort study. Clin Epidemiol 2014 Nov 13:405\u0026ndash;21.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBoonsarngsuk V, Mangkang K, Santanirand P. Prevalence and risk factors of drug-resistant extrapulmonary tuberculosis. Clin Respir J. 2018;12(6):2101\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDusthackeer A, Sekar G, Chidambaram S, Kumar V, Mehta P, Swaminathan S. Drug resistance among extrapulmonary TB patients: Six years experience from a supranational reference laboratory. Indian J Med Res. 2015;142(5):568\u0026ndash;74.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMaurya AK, Kant S, Nag VL, Kushwaha RA, Dhole TN. Trends of anti-tuberculosis drug resistance pattern in new cases and previously treated cases of extrapulmonary tuberculosis cases in referral hospitals in northern India. J Postgrad Med. 2012;58(3):185\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMiiro E, Olum R, Baluku JB. Clinical features, resistance patterns and treatment outcomes of drug-resistant extra-pulmonary tuberculosis: A scoping review. J Clin Tuberculosis Other Mycobact Dis. 2023;33:100390.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis. 2015;78(2):47.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCollins JM, Kipiani M, Jin Y, Sharma AA, Tomalka JA, Avaliani T, Gujabidze M, Bakuradze T, Sabanadze S, Avaliani Z, Blumberg HM. Pharmacometabolomics in TB meningitis\u0026mdash;Understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid. PLoS ONE. 2025;20(3):e0315999.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). Wellcome open Res. 2018;3:83.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFord CB, Shah RR, Maeda MK, Gagneux S, Murray MB, Cohen T, Johnston JC, Gardy J, Lipsitch M, Fortune SM. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013;45(7):784\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAtavliyeva S, Auganova D, Tarlykov P. Genetic diversity, evolution and drug resistance of Mycobacterium tuberculosis lineage 2. Front Microbiol. 2024;15:1384791.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSatti H, McLaughlin MM, Seung KJ, Becerra MC, Keshavjee S. High risk of drug-resistant tuberculosis when first-line therapy fails in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2013;17(1):100\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYe Y, Hu X, Shi Y, Zhou J, Zhou Y, Song X, Xie Y, Lu X, Wang L, Ying B, Chen X. Clinical features and drug-resistance profile of urinary tuberculosis in south-western China: a cross-sectional study. Medicine. 2016;95(19):e3537.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWang DM, Li QF, Zhu M, Xu YH, Liao Y. Clinical characteristics, common sites and drug resistance profile in culture-confirmed extrapulmonary TB/HIV co-infection patients, Southwest China. J Global Antimicrob Resist. 2022;28:1\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSchwab TC, Perrig L, G\u0026ouml;ller PC, De la Hoz FF, Lahousse AP, Minder B, G\u0026uuml;nther G, Efthimiou O, Omar SV, Egger M, Fenner L. Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2024;24(10):1162\u0026ndash;76.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGao W, Yang C, Wang T, Guo Y, Zeng Y. Nanopore-based targeted next-generation sequencing of tissue samples for tuberculosis diagnosis. Front Microbiol. 2024;15:1403619.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYu S, Liu N, Xie Z, Zeng Y, Wang H, Wang Q, Li P, Li H, Sun J, Zhu Q, Gao W. Nanopore sequencing for precise detection of Mycobacterium tuberculosis and drug resistance: a retrospective multicenter study in China. J Clin Microbiol. 2025;63(4):e01813\u0026ndash;24.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMathys V, Wintjens R, Lefevre P, Bertout J, Singhal A, Kiass M, Kurepina N, Wang XM, Mathema B, Baulard A, Kreiswirth BN. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009;53(5):2100\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChen J, Zhang S, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017;72(12):3272\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJing W, Pang Y, Zong Z, Wang J, Guo R, Huo F, Jiang G, Ma Y, Huang H, Chu N. Rifabutin resistance associated with double mutations in rpoB gene in Mycobacterium tuberculosis isolates. Front Microbiol. 2017;8:1768.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eShi T, Shou F, He Y, Zhou K, Gao W, Nie X, Han M, Liao C, Li T. Whole genome sequencing of drug resistance Mycobacterium tuberculosis from extra-pulmonary sites. Life Sci Alliance. 2023;6(11).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLee J, Armstrong DT, Ssengooba W, Park JA, Yu Y, Mumbowa F, Namaganda C, Mboowa G, Nakayita G, Armakovitch S, Chien G. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first-and second-line drugs. Antimicrob Agents Chemother. 2014;58(1):11\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSeemann T. Snippy: rapid haploid variant calling and core genome alignment. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://github.com/tseemann/snippy\u003c/span\u003e\u003cspan address=\"https://github.com/tseemann/snippy\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Accessed 2 Feb 2015.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJung Y, Han D, BWA-MEME. BWA-MEM emulated with a machine learning approach. Bioinformatics. 2022;38(9):2404\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGarrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907 [Preprint]. 20 Jul 2012 [cited 2025 Nov 27]. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.48550/arXiv.1207.3907\u003c/span\u003e\u003cspan address=\"10.48550/arXiv.1207.3907\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCingolani P, Platts A, Wang LL, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80\u0026ndash;92.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCroucher NJ, Page AJ, Connor TR, et al. Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using Gubbins. Nucleic Acids Res. 2015;43(3):e15.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMinh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37(5):1530\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLetunic I, Bork P. Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation. Nucleic Acids Res. 2021;49(W1):W293\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVerboven L, Phelan J, Heupink TH, Van Rie A. TBProfiler for automated calling of the association with drug resistance of variants in Mycobacterium tuberculosis [published correction appears in. PLoS ONE. 2023;18(10):e0293254.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWorld Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2nd ed. Geneva: WHO; 2023.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWanstrath C, Chacon S, Werner TP, Hyett PJ. GitHub: build and ship software on a single, collaborative platform. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://github.com/\u003c/span\u003e\u003cspan address=\"https://github.com/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e. Accessed Feb 2008.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eReddy TB, Riley R, Wymore F, et al. TB database: an integrated platform for tuberculosis research. Nucleic Acids Res. 2009;37(Database issue):D499\u0026ndash;508.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChakravorty S, Simmons AM, Rowneki M, et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio. 2017;8(4):e00812\u0026ndash;17.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eShanmugam SK, Kumar N, Sembulingam T, et al. Mycobacterium tuberculosis lineages associated with mutations and drug resistance in isolates from India. Microbiol Spectr. 2022;10(3):e0159421.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKant S, Maurya AK, Nag VL, Bajpai J. Rising trend of drug resistance among extrapulmonary. TB North India. 2018;52(suppl 62):PA3681.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVidyaRaj CK, Vadakunnel MJ, Mani BR, et al. Prevalence of extrapulmonary tuberculosis and factors influencing successful treatment outcomes among notified cases in South India. Sci Rep. 2025;15(1):8290.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHillemann D, R\u0026uuml;sch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2007;45(8):2635\u0026ndash;40.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCausse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M. Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2008;12(12):1456\u0026ndash;60.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHuyen MN, Tiemersma EW, Lan NT, et al. Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis. 2010;10:149.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAndres S, Hillemann D, R\u0026uuml;sch-Gerdes S, Richter E. Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany. Antimicrob Agents Chemother. 2014;58(1):590\u0026ndash;2.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eClick ES, Kurbatova EV, Alexander H, et al. Isoniazid and rifampin-resistance mutations associated with resistance to second-line drugs and with sputum culture conversion. J Infect Dis. 2020;221(12):2072\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eForson A, Kudzawu S, Kwara A, Flanigan T. High frequency of first-line anti-tuberculosis drug resistance among persons with chronic pulmonary tuberculosis at a teaching hospital chest clinic. Ghana Med J. 2010;44(2):42\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDagne B, Desta K, Fekade R, et al. The epidemiology of first and second-line drug-resistance Mycobacterium tuberculosis complex common species: evidence from selected TB treatment initiating centers in Ethiopia. PLoS ONE. 2021;16(1):e0245687.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAbdelgawad N, Wasserman S, Gausi K et al. Population pharmacokinetics of rifampicin in plasma and cerebrospinal fluid in adults with tuberculosis meningitis. J Infect Dis. 2025 Apr 29.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAbdelgawad N, Wasserman S, Abdelwahab MT, et al. Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis. J Infect Dis. 2024;229(4):1200\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRuslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27\u0026ndash;35.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDonald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90(5):279\u0026ndash;92.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBespiatykh D, Bespyatykh J, Mokrousov I, Shitikov E. A comprehensive map of Mycobacterium tuberculosis complex regions of difference. mSphere. 2021;6(4):e0053521.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNiemann S, Diel R, Khechinashvili G, et al. Mycobacterium tuberculosis Beijing lineage favors the spread of multidrug-resistant tuberculosis in the Republic of Georgia. J Clin Microbiol. 2010;48(10):3544\u0026ndash;50.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHakamata M, Takihara H, Iwamoto T, et al. Higher genome mutation rates of Beijing lineage of Mycobacterium tuberculosis during human infection. Sci Rep. 2020;10(1):17997.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDu DH, Geskus RB, Zhao Y, et al. Correction: the effect of M. tuberculosis lineage on clinical phenotype. PLOS Glob Public Health. 2024;4(8):e0003674.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCohen T, van Helden PD, Wilson D, et al. Mixed-strain Mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev. 2012;25(4):708\u0026ndash;19.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1: Clinical and microbiological characteristics of study cohort\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"539\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eClinical characteristic\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eTotal no of patients (n)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e117\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eMale, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e68 (58.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eMale, age in years, median (IQR)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e37 (30.0-48.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eFemale, age in years, median (IQR)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e33 (24.5-55.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSample type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 142px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eCerebrospinal fluid (CSF), n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e40 (34.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003ePus, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e35 (29.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eFine needle aspiration cytology (FNAC), n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e22 (18.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eTissue, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e8 (6.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eIleocecal biopsy (ICBx), n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e6 (5.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eSynovial fluid (SF), n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e5 (4.3%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eVitreous fluid (VF), n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e1 (0.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 397px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMYOCTBI profile\u003csup\u003e1\u003c/sup\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 142px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eDS-TB\u003csup\u003e2\u003c/sup\u003e, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e89 (76.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eHR-TB\u003csup\u003e3\u003c/sup\u003e, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e17 (14.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eRR-TB\u003csup\u003e4\u003c/sup\u003e, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e2 (1.7%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003eMDR-TB\u003csup\u003e5\u003c/sup\u003e, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e1 (0.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003ePre-XDR TB\u003csup\u003e6\u003c/sup\u003e, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e8 (6.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 397px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 142px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eMYCOTBI profile was classified according to the latest WHO guidelines\u003csup\u003e1\u003c/sup\u003e, Drug sensitive tuberculosis\u003csup\u003e2\u003c/sup\u003e, Isoniazid-resistant tuberculosis\u003csup\u003e3\u003c/sup\u003e, Rifampicin-resistant tuberculosis\u003csup\u003e4\u003c/sup\u003e, Multidrug-resistant tuberculosis\u003csup\u003e5\u003c/sup\u003e, Pre-extensively drug-resistant tuberculosis\u003csup\u003e6\u003c/sup\u003e,IQR; Interquartile range\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2A: Sequencing statistics of 117 \u003cem\u003eM. tuberculosis\u003c/em\u003e genomes from EPTB samples\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"598\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSample type (n)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMean baseQ,\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003emedian (IQR)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eReads mapped to H37Rv (n)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eH37Rv genome coverage (%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eH37Rv genome coverage depth (x)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eCSF (40)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e37.6 (36.8-38.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e4,958,397\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e99 (98.8-99.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e257 (144.3-339.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003ePus (35)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e37.4 (36.8-38.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e6107067\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e99.2 (98.9-99.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e320 (199.5-417.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eFNAC (22)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e37.3 (37-37.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e3,408,569\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e98.9 (98.5-99.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e143 (111.8-176.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eTissue (8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e38.5 (38.4-38.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e2,244,612\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e99.4 (99.3-99.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e143 (78-296.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eICBx (6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e36.9 (36.8-37.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e3447245\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e99.4 (99.2-99.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e141 (124.2-158.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eSF (5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e38.5 (37.3-38.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e2,707,173\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e99.4 (99-99.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e158 (101-230)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eVF (1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e36.9\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e3,284,058\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e98.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e132\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 114px;\"\u003e\n \u003cp\u003eTotal samples\u003c/p\u003e\n \u003cp\u003e(117)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e37.3 (36.8-38.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e3,992,798\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 126px;\"\u003e\n \u003cp\u003e99.1 (98.8-99.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 131px;\"\u003e\n \u003cp\u003e201 (122-339)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eCSF- Cerebrospinal fluid,\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eFNAC\u003cstrong\u003e-\u003c/strong\u003e Fine-needle aspiration cytology, ICBx- Ileocaecal biopsy, SF- Synovial fluid, VF-Vitreous fluid, IQR- Interquartile range\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2B: Drug resistance mutation profiles with the number of samples carrying mutations conferring drug resistance. The samples are classified according to the updated WHO catalog.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"661\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSamples with resistance (n)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDrug affected\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eGene\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMutation\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eWHO classification\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eRifampicin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003erpoB\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.Ser450Leu\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eRifampicin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003erpoB\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.Asp435Val\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eRifampicin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003erpoB\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.His445Asn\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eRifampicin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003erpoB\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 195px;\"\u003e\n \u003cp\u003erpoB p.Leu452Pro\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eIsoniazid\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003ekatG\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.Ser315Thr\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eIsoniazid/Ethionamide\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003efabG1\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ec.-15C\u0026gt;T\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIsoniazid/Ethionamide\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cem\u003efabG1\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003ec.-8T\u0026gt;G\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eEthionamide\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003eethA\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ec.449_481del\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eIR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eStreptomycin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003egid\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ec.102delG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eIR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eStreptomycin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003egid\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ec.115delC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eIR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eStreptomycin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003egid\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ec.137dupA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eIR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eStreptomycin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003erpsL\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.Lys43Arg\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eAminoglycosides*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003errs\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003en.1401A\u0026gt;G\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eFluoroquinolone\u003csup\u003e#\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003egyrA\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.Asp94Gly / p.Asp94Tyr\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eEthambutol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003eembB\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 195px;\"\u003e\n \u003cp\u003eembB p.Gly406Asp\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003eEthambutol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003eembB\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.Met306Leu\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003ePyrazinamide\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003epncA\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 195px;\"\u003e\n \u003cp\u003ep.Leu27Pro\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003ePyrazinamide\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003epncA\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 195px;\"\u003e\n \u003cp\u003epncA p.Lys96Thr\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 102px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 159px;\"\u003e\n \u003cp\u003ePyrazinamide\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 87px;\"\u003e\n \u003cp\u003e\u003cem\u003epncA\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 195px;\"\u003e\n \u003cp\u003epncA p.Val139Ala\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 118px;\"\u003e\n \u003cp\u003e\u0026nbsp;AR\u003csup\u003e$\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAR\u003csup\u003e$\u003c/sup\u003e- Associated with resistance, IR\u003csup\u003e$\u003c/sup\u003e-Associated with resistance interim;\u003csup\u003e\u0026nbsp;#\u003c/sup\u003eFluoroquinolone- Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin; *Aminoglycosides- Amikacin, Capreomycin, Kanamycin\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3: Samples showing heteroresistance based on the reads mapped to both mutant and wild-type strains\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"630\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eSample ID\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 85px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eReference nucleotide\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 89px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eNucleotide position\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 85px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMutation nucleotide\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 125px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eAntibiotic\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 156px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eTotal reads (Reference: Mutant)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003ePus_3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e761139\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eRifampicin\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e15:231\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e761155\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eRifampicin\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e245:13\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e781687\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eStreptomycin\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e251:10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e4247429\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eEthambutol\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e297:10\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e2155168\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eIsoniazid\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e339:11\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003eCSF_12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e2288955\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003ePyrazinamide\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e88:281\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e7582\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eFluoroquinolone\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e77:211\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e4247429\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eEthambutol\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e73:192\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e2155168\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eIsoniazid\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e108:289\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e1673425\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eIsoniazid\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e72:179\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e761110\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eT\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eRifampicin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e54:126\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e1472751\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eStreptomycin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e73:125\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003eCSF_43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e781687\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eStreptomycin\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e45:23\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\" style=\"width: 90px;\"\u003e\n \u003cp\u003eCSF_8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 89px;\"\u003e\n \u003cp\u003e4247863\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 85px;\"\u003e\n \u003cp\u003eG\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 125px;\"\u003e\n \u003cp\u003eEthambutol\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\" style=\"width: 156px;\"\u003e\n \u003cp\u003e298:18\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eCSF - Cerebrospinal fluid\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-genomics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"gics","sideBox":"Learn more about [BMC Genomics](http://bmcgenomics.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/gics","title":"BMC Genomics","twitterHandle":"#BMCGenomics","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"EPTB, lineage, drug resistance, whole genome sequencing, MYCOTBI","lastPublishedDoi":"10.21203/rs.3.rs-7813203/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7813203/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eCertain \u003cem\u003eM. tuberculosis\u003c/em\u003e lineages may preferentially infect extrapulmonary sites, potentially influencing clinical outcomes. Poor drug penetration at these sites may cause treatment failure, even in the absence of resistance. Timely access to resistance profiles and lineage information may support more effective, personalized treatment for extrapulmonary tuberculosis (EPTB). We sequenced 117 \u003cem\u003eM. tuberculosis\u003c/em\u003e culture isolates from seven EPTB sites at PGIMER, Chandigarh, India. This included cerebrospinal fluid (CSF, n\u0026thinsp;=\u0026thinsp;40), pus (n\u0026thinsp;=\u0026thinsp;35), fine-needle aspiration cytology (FNAC, n\u0026thinsp;=\u0026thinsp;22), tissue (n\u0026thinsp;=\u0026thinsp;8), ileocaecal biopsy (n\u0026thinsp;=\u0026thinsp;6), synovial fluid (n\u0026thinsp;=\u0026thinsp;5), and vitreous fluid (n\u0026thinsp;=\u0026thinsp;1). Phenotypic drug susceptibility testing (pDST) against 12 drugs was performed using the MYCOTBI sensititre assay. Whole genome sequencing (WGS) on Illumina XTen platform and analyzed using in-house pipelines.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e\u003cp\u003eDrug resistance was identified in 23.9% (28/117) of isolates by pDST and 29.9% (35/117) by WGS, with 93.0% concordance. WGS detected additional resistant cases missed by MYCOTBI (p\u0026thinsp;=\u0026thinsp;0.039). Resistance was significantly associated with sample type (p\u0026thinsp;=\u0026thinsp;0.0446), highest in CSF (16/40, 40.0%). Lineage 2 had the highest resistance (13/24, 54.1%), primarily from CSF (9/13, 69.2%). Mixed infections were observed in 6.8% (8/117) of isolates, mostly involving lineages 2 and 3. Heteroresistance was more common in mixed infections (p\u0026thinsp;=\u0026thinsp;0.0139).\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e\u003cp\u003eWGS reliably detected resistance to anti-TB drugs, along with lineage and mixed infections. This approach can be applied in culture-free targeted sequencing for rapid detection of resistance and lineage, enabling personalized treatment regimens and improved outcomes in EPTB.\u003c/p\u003e","manuscriptTitle":"Genomic insights into extrapulmonary tuberculosis reveal enrichment of lineage 2 with high drug resistance in specific clinical phenotypes","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-12-04 08:42:53","doi":"10.21203/rs.3.rs-7813203/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-03-31T18:20:53+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-02-28T05:06:51+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"106671953629538421281633062986280914542","date":"2026-02-06T07:43:52+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-02-05T04:12:59+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"148388760166621356333320846988428915496","date":"2026-02-05T03:55:11+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"113782483941979765845563588543862718169","date":"2026-02-03T08:45:28+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2026-01-22T14:46:49+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-12-29T05:43:44+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"193935761604945534715554626988831164811","date":"2025-12-07T14:29:35+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"84560198724498370689776043418737842698","date":"2025-12-04T14:14:40+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"137649869676919222955448324517896518505","date":"2025-12-02T14:11:31+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-12-02T14:04:08+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-10-21T22:26:46+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-10-21T22:26:15+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Genomics","date":"2025-10-09T05:18:46+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-genomics","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"gics","sideBox":"Learn more about [BMC Genomics](http://bmcgenomics.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/gics","title":"BMC Genomics","twitterHandle":"#BMCGenomics","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"e81c5100-b2ed-43fe-9007-282bb756c903","owner":[],"postedDate":"December 4th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-04-14T12:54:25+00:00","versionOfRecord":[],"versionCreatedAt":"2025-12-04 08:42:53","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7813203","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7813203","identity":"rs-7813203","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}